EP3134102B1 - Superagonisten, partielle agonisten und antagonisten von interleukin-2 - Google Patents
Superagonisten, partielle agonisten und antagonisten von interleukin-2 Download PDFInfo
- Publication number
- EP3134102B1 EP3134102B1 EP15782644.7A EP15782644A EP3134102B1 EP 3134102 B1 EP3134102 B1 EP 3134102B1 EP 15782644 A EP15782644 A EP 15782644A EP 3134102 B1 EP3134102 B1 EP 3134102B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mutein
- cells
- cell
- wild
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims description 612
- 239000005557 antagonist Substances 0.000 title claims description 31
- 102000000588 Interleukin-2 Human genes 0.000 title description 584
- 239000004031 partial agonist Substances 0.000 title description 25
- 230000002483 superagonistic effect Effects 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims description 273
- 230000027455 binding Effects 0.000 claims description 164
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 120
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 104
- 102000005962 receptors Human genes 0.000 claims description 87
- 238000006467 substitution reaction Methods 0.000 claims description 80
- 230000002829 reductive effect Effects 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 102000003812 Interleukin-15 Human genes 0.000 claims description 48
- 108090000172 Interleukin-15 Proteins 0.000 claims description 48
- 102200131576 rs121912452 Human genes 0.000 claims description 47
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 45
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 102220427331 c.274A>T Human genes 0.000 claims description 44
- 230000011664 signaling Effects 0.000 claims description 41
- 210000000822 natural killer cell Anatomy 0.000 claims description 39
- 102200142011 rs121909050 Human genes 0.000 claims description 39
- 102200077167 rs2275591 Human genes 0.000 claims description 37
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 35
- 102200006514 rs121913236 Human genes 0.000 claims description 35
- 102200158049 rs387906619 Human genes 0.000 claims description 34
- 230000035755 proliferation Effects 0.000 claims description 32
- 230000026731 phosphorylation Effects 0.000 claims description 27
- 238000006366 phosphorylation reaction Methods 0.000 claims description 27
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 23
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 23
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 22
- 102220535585 Tyrosine-protein kinase Fgr_S130R_mutation Human genes 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 17
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 16
- 208000024908 graft versus host disease Diseases 0.000 claims description 16
- 230000004069 differentiation Effects 0.000 claims description 15
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims 2
- 230000014509 gene expression Effects 0.000 description 103
- 235000001014 amino acid Nutrition 0.000 description 91
- 108020003175 receptors Proteins 0.000 description 86
- 238000000034 method Methods 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 48
- 150000007523 nucleic acids Chemical class 0.000 description 46
- 239000013598 vector Substances 0.000 description 46
- 102000039446 nucleic acids Human genes 0.000 description 45
- 108020004707 nucleic acids Proteins 0.000 description 45
- 230000035772 mutation Effects 0.000 description 44
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 42
- 230000000694 effects Effects 0.000 description 41
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 33
- 239000000872 buffer Substances 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 102000004127 Cytokines Human genes 0.000 description 26
- 108090000695 Cytokines Proteins 0.000 description 26
- 230000006870 function Effects 0.000 description 26
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 21
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 18
- 238000000684 flow cytometry Methods 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 102220606633 Zinc finger protein GLIS1_Q74N_mutation Human genes 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 108700004922 F42A Proteins 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000238631 Hexapoda Species 0.000 description 11
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 11
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 description 11
- 239000000556 agonist Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 229960005395 cetuximab Drugs 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 201000004681 Psoriasis Diseases 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 210000003289 regulatory T cell Anatomy 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000012552 review Methods 0.000 description 10
- 230000002269 spontaneous effect Effects 0.000 description 10
- 108010004729 Phycoerythrin Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- -1 coatings Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000005734 heterodimerization reaction Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 230000002101 lytic effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 102220058213 rs730881465 Human genes 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 7
- 102000009109 Fc receptors Human genes 0.000 description 7
- 108010087819 Fc receptors Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102200005671 rs1013940 Human genes 0.000 description 7
- 102220234844 rs1131690927 Human genes 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 238000000670 ligand binding assay Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 238000003559 RNA-seq method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 229960002806 daclizumab Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000003463 hyperproliferative effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 4
- 108010002335 Interleukin-9 Proteins 0.000 description 4
- 208000001126 Keratosis Diseases 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 4
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108010000605 Ribosomal Proteins Proteins 0.000 description 4
- 102000002278 Ribosomal Proteins Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 238000000329 molecular dynamics simulation Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102100035841 60S ribosomal protein L7 Human genes 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 3
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000853617 Homo sapiens 60S ribosomal protein L7 Proteins 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 3
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008484 agonism Effects 0.000 description 3
- 108700025316 aldesleukin Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000033300 receptor internalization Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 101710189311 Cytokine receptor common subunit gamma Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940124753 IL-2 agonist Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 2
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000101040 Pityriasis Species 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 101150063267 STAT5B gene Proteins 0.000 description 2
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 229940087463 proleukin Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000000438 stratum basale Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000042286 type I cytokine receptor family Human genes 0.000 description 2
- 108091052247 type I cytokine receptor family Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
- 108010060632 Interleukin-2 Receptor beta Subunit Proteins 0.000 description 1
- 102000008193 Interleukin-2 Receptor beta Subunit Human genes 0.000 description 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 description 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038414 Interleukin-9 Receptors Proteins 0.000 description 1
- 102000010682 Interleukin-9 Receptors Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100039641 Protein MFI Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000005134 atomistic simulation Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 102220452462 c.242G>T Human genes 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000007451 chromatin immunoprecipitation sequencing Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000003348 filter assay Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000023368 generalized pustular psoriasis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 102000035085 multipass transmembrane proteins Human genes 0.000 description 1
- 108091005494 multipass transmembrane proteins Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 102220234588 rs1114167484 Human genes 0.000 description 1
- 102200004150 rs147750704 Human genes 0.000 description 1
- 102220082053 rs201520438 Human genes 0.000 description 1
- 102200076656 rs34991226 Human genes 0.000 description 1
- 102200035601 rs387907134 Human genes 0.000 description 1
- 102200032604 rs5030773 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- Interleukin 2 is a pluripotent cytokine produced primarily by activated CD4 + T cells, which plays a crucial role in producing a normal immune response.
- IL-2 promotes proliferation and expansion of activated T lymphocytes, potentiates B cell growth, and activates monocytes and natural killer cells. It was by virtue of these activities that IL-2 was tested and is used as an approved treatment of cancer (aldesleukin, Proleukin®).
- human IL-2 is synthesized as a precursor polypeptide of 153 amino acids, from which 20 amino acids are removed to generate mature secreted IL-2 (Taniguchi 1983).
- Recombinant human IL-2 has been produced in E. coli (Rosenberg 1984), in insect cells (Smith 1985) and in mammalian COS cells (Taniguchi 1983).
- Interleukin-2 is a four ⁇ -helical bundle type I cytokine first identified as a T cell growth factor ( Morgan et al., Science 193: 1007 (1976 )) but subsequently shown to have broad actions. IL-2 promotes T helper differentiation ( Zhu et al., Annual review of immunology 28: 445 (2010 ); Liao et al., Nat Immunol 9: 1288 (2008 ); and Liao et al., Nat Immunol 12: 551 (2011 )) and the development of regulatory T (Treg) cells ( Cheng et al., Immunol Rev 241: 63 (2011 )), induces natural killer and lymphokine activated killer activity ( Liao et al., Immunity 38: 13 (2013 )), and mediates activation-induced cell death (AICD) ( Lenardo et al., Nature 353: 858 (1991 )).
- T helper differentiation Zhu et al., Annual review of
- IL-2 works by interacting with three different receptors: the interleukin 2 receptor alpha (IL-2R ⁇ ; CD25), the interleukin 2 receptor beta (IL-2R ⁇ ;CD122), and the interleukin 2 receptor gamma (IL-2R ⁇ ;CD132; common gamma chain).
- the first receptor to be identified was the IL-2R ⁇ , which is a 55 kD polypeptide (p55) that appears upon T cell activation and was originally called Tac (for T activation) antigen.
- the IL-2R ⁇ binds IL-2 with a K d of approximately 10 -8 M, and is also known as the "low affinity" IL-2 receptor. Binding of IL-2 to cells expressing only the IL-2R ⁇ does not lead to any detectable biologic response.
- ⁇ c is shared by the receptors for IL-4, IL-7, IL-9, IL-15, and IL-21 ( Leonard et al., Nature Reviews Immunology 1: 200 (2001 )) and encoded by the gene mutated in humans with X-linked severe combined immunodeficiency ( Noguchi et al., Cell 73: 147 (Apr 9, 1993 )), IL-2R ⁇ is shared by the receptor for IL-15 ( Waldmann, Nature Reviews Immunology 6: 595 (2006 )), a cytokine that is critical for normal development of NK cells and memory CD8 + T cells ( Waldmann, Nature Reviews Immunology 6: 595 (2006 )).
- IL-2 and IL-15 bound to their receptors provide insights into receptor assembly and signaling ( Wang et al., Science 310: 1159 (2005 ); and Ring et al., Nat Immunol 13: 1187 (2012 )).
- IL-2 and IL-15 can promote pathologic responses, and a therapeutic goal is to maintain desired actions of these cytokines while blocking untoward autoimmune or immunosuppressive responses.
- mAbs monoclonal antibodies to human IL-2R ⁇ , Daclizumab and Basiliximab, are approved by the FDA and exhibit efficacy in renal transplantation rejection ( Vincenti et al., N Engl J Med 338: 161 (1998 )), cardiac transplantation ( Hershberger et al., N Engl J Med 352: 2705 (2005 )), multiple sclerosis ( Gold et al., Lancet 381: 2167 (2013 )), and asthma ( Bielekova et al., Proc Natl Acad Sci U S A 101: 8705 (2004 ); and Busse et al., Am J Respir Crit Care Med 178: 1002 (2008 )) but they do not block IL-2 signaling via intermediate affinity IL-2R ⁇ - ⁇ c receptors expressed on NK and memory CD8 + cells and cannot block IL-15 signaling ( Tkaczuk et al., Am J Transplant 2: 31 (2002 )).
- antihuman IL-2R ⁇ mAb Mik ⁇ 1 can block trans-presentation of IL-2 and IL-15 to cells expressing IL-2R ⁇ - ⁇ c receptors ( Morris et al., Proc Natl Acad Sci U S A 103: 401 (2006 )), it is relatively ineffective in blocking cis-signaling by IL-2 or IL-15 via their high affinity heterotrimeric receptor complexes ( Morris et al., Proc Natl Acad Sci U S A 103: 401 (2006 ); and Waldmann et al., Blood 121: 476 (2013 )). As such, new IL-2 muteins that can block one or more IL-2 and/or IL-15 functions are needed.
- IL-2R binding protein which can block IL-2 function and which has substitutions: 18R, 22E, 80F, 81D, 85V, 86V,92F and 1261 is described in U2014/046026.
- the present disclosure provides novel IL-2 muteins that function as IL-2 partial agonists and antagonists.
- IL-2 exerts a wide spectrum of effects on the immune system, and it plays crucial roles in regulating both immune activation and homeostasis.
- IL-2 As an immune system stimulator, IL-2 has found use in the treatment of cancer and chronic viral infections. The stimulatory affects of IL-2 can also cause havoc, mediating autoimmunity and transplant rejection. Because of its instrumental role in immune regulation and disease, the identification of new IL-2 molecules such as IL-2 partial agonists and antagonists remains an active area of research.
- IL-2 works through three different receptors: the IL-2R ⁇ , the IL-2R ⁇ , and the IL-2R ⁇ .
- Most cells, such as resting T cells, are not responsive to IL-2 since they only express the IL-2R ⁇ , and the IL-2R ⁇ , which have low affinity for IL-2.
- resting T cells Upon stimulation, resting T cells express the relatively high affinity IL-2 receptor IL-2R ⁇ . Binding of IL-2 to the IL-2R ⁇ causes this receptor to sequentially engage the IL-2R ⁇ , and the IL-2R ⁇ , bringing about T cell activation.
- IL-2 "superkines” with augmented action due to enhanced binding affinity for IL-2R ⁇ were previously developed ( Levin et al., Nature 484: 529 (2012 )). It was hypothesized that this high-affinity superkine/IL-2R ⁇ complex could serve as a dominant-negative scaffold to create a "receptor signaling clamp" to block endogenous signaling.
- Novel human interleukin-2 (IL-2) muteins or variants thereof are provided herein.
- IL-2 muteins that have an increased binding capacity for IL-2R ⁇ receptor and a decreased binding capacity to IL-2R ⁇ c receptor.
- Such IL-2 muteins find use, for example, as IL-2 partial agonists and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g ., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia).
- pharmaceutical compositions that include such IL-2 muteins and uses of such IL-2 muteins.
- an IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 (hIL-2 wherein the IL-2 mutein comprises the amino acid substitutions L18R, Q22E, L80F, R81D, L85V, I86V, I92F, Q126T, and S130R.
- the subject IL-2 mutein has a reduced capability to stimulate STAT5 phosphorylation in an IL-2R ⁇ + T cell as compared to wild-type hIL-2.
- the T cell is a CD8+ T cell.
- the subject IL-2 mutein has a reduced capability to stimulate the pERK1/ERK2 signaling in a IL-2R ⁇ + cell as compared to wild-type hIL-2.
- the subject IL-2 mutein is an IL-2 and/or IL-15 antagonist.
- the IL-2 mutein is an inhibitor of IL-2 and/or IL-15 STAT5 phosphorylation in CD8+ T cells.
- the IL-2 mutein is an inhibitor of IL-2 and/or IL-15 induced proliferation of CD8+ T cells.
- the IL-2 mutein is an inhibitor of IL-2 dependent, TCR-induced cell proliferation.
- the IL-2 mutein is an inhibitor of IL-2 dependent Th1, Th9 and/or Treg differentiation.
- the IL-2 mutein is a promoter of Th17 differentiation.
- the mutein is an inhibitor of IL-2 dependent activation of NK cells.
- an IL-2 mutein fusion protein comprising any one of the IL-muteins described herein linked to a human Fc antibody fragment.
- a pharmaceutical composition comprising any one of the IL-2 muteins or the IL-2 mutein fusion protein described herein and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising the IL-2 mutein described herein, and a pharmaceutically acceptable carrier, for use in treating graft versus host disease (GVHD).
- a pharmaceutical composition comprising the IL-2 mutein described herein, and a pharmaceutically acceptable carrier, for use in treating adult T cell leukemia.
- IL-2 means wild-type IL-2, whether native or recombinant.
- Mature human IL-2 occurs as a 133 amino acid sequence (less the signal peptide, consisting of an additional 20 N-terminal amino acids), as described in Fujita, et. al., PNAS USA, 80, 7437-7441 (1983 ).
- the amino acid sequence of human IL-2 (SEQ ID NO: 1) is found in Genbank under accession locator NP_000577.2.
- the amino acid sequence of mature human IL-2 is depicted in SEQ ID NO: 2.
- the murine ( Mus musculus ) IL-2 amino acid sequence is found in Genbank under accession locator (SEQ ID NO: 3).
- the amino acid sequence of mature murine IL-2 is depicted in SEQ ID NO: 4.
- IL-2 mutein means an IL-2 polypeptide wherein specific substitutions to the interleukin-2 protein have been made.
- the IL-2 muteins are characterized by amino acid insertions, deletions, substitutions and modifications at one or more sites in or at the other residues of the native IL-2 polypeptide chain.
- any such insertions, deletions, substitutions and modifications result in an IL-2 mutein that retains the IL-2R ⁇ binding activity.
- Exemplary muteins can include substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids.
- Muteins also include conservative modifications and substitutions at other positions of IL-2 (i.e., those that have a minimal effect on the secondary or tertiary structure of the mutein). Such conservative substitutions include those described by Dayhoff in The Atlas of Protein Sequence and Structure 5 (1978 ), and by Argos in EMBO J., 8:779-785 (1989 ).
- amino acids belonging to one of the following groups represent conservative changes: Group I: ala, pro, gly, gln, asn, ser, thr; Group II: cys, ser, tyr, thr; Group III:val, ile, leu, met, ala, phe; Group IV: lys, arg, his; Group V: phe, tyr, trp, his; and Group VI: asp, glu.
- “Numbered in accordance with IL-2” means identifying a chosen amino acid with reference to the position at which that amino acid normally occurs in the mature sequence of wild type IL-2, for example R81 refers to the eighty-first amino acid, arginine, that occurs in SEQ ID NO: 2.
- cell types having the IL-2R ⁇ receptor means the cells known to have this receptor type, i.e., T cells, activated T cells, B cells, activated monocytes, and activated NK cells.
- cell types having the IL-2R ⁇ receptor means the cells known to have that receptor type, i.e., B cells, resting monocytes, and resting NK cells.
- identity refers to the subunit sequence identity between two molecules. When a subunit position in both of the molecules is occupied by the same monomeric subunit (i.e., the same amino acid residue or nucleotide), then the molecules are identical at that position.
- the similarity between two amino acid or two nucleotide sequences is a direct function of the number of identical positions. In general, the sequences are aligned so that the highest order match is obtained. If necessary, identity can be calculated using published techniques and widely available computer programs, such as the GCS program package ( Devereux et al., Nucleic Acids Res.
- Sequence identity can be measured using sequence analysis software such as the Sequence Analysis Software Package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, Wis. 53705 ), with the default parameters thereof.
- polypeptide refers to any chain of amino acid residues, regardless of its length or post-translational modification (e.g., glycosylation or phosphorylation).
- mutant IL-2 polypeptides of the disclosure are “substantially pure,” they can be at least about 60% by weight (dry weight) the polypeptide of interest, for example, a polypeptide containing the mutant IL-2 amino acid sequence.
- the polypeptide can be at least about 75%, about 80%, about 85%, about 90%,about 95% or about 99%, by weight, the polypeptide of interest. Purity can be measured by any appropriate standard method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- An "agonist” is a compound that interacts with a target to cause or promote an increase in the activation of the target.
- a "partial agonist” is a compound that interacts with the same target as an agonist but does not produce as great a magnitude of a biochemical and/or physiological effect as the agonist, even by increasing the dosage of the partial agonist.
- a "super agonist” is a type of agonist that is capable of producing a maximal response greater than the endogenous agonist for the target receptor, and thus has an efficacy of more than 100%.
- an “antagonist” is a compound that opposes the actions of an agonist, e.g. by preventing, reducing, inhibiting, or neutralizing the activity of an agonist.
- An “antagonist” can also prevent, inhibit, or reduce constitutive activity of a target, e.g ., a target receptor, even where there is no identified agonist.
- operably linked is intended to mean that the nucleotide sequence of interest (i.e., a sequence encoding an IL-2 mutein) is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- regulatory sequences include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). See , for example, Goeddel (1990) in Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, Calif .).
- Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
- the expression constructs of the invention can be introduced into host cells to thereby produce the human IL-2 muteins disclosed herein or to produce biologically active variants thereof.
- host cell and "recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell but are still included within the scope of the term as used herein.
- transformation and “transfection” refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, particle gun, or electroporation.
- foreign nucleic acid e.g., DNA
- a host cell including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, particle gun, or electroporation.
- the term "pharmaceutically acceptable carrier” includes, but is not limited to, saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- Supplementary active compounds e.g., antibiotics
- cancer or “cancerous”
- hyperproliferative or “hyperproliferative”
- neoplastic to refer to cells having the capacity for autonomous growth (i.e., an abnormal state or condition characterized by rapidly proliferating cell growth).
- hyperproliferative and neoplastic disease states may be categorized as pathologic (i.e., characterizing or constituting a disease state), or they may be categorized as non-pathologic (i.e., as a deviation from normal but not associated with a disease state).
- pathologic i.e., characterizing or constituting a disease state
- non-pathologic i.e., as a deviation from normal but not associated with a disease state.
- the terms are meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
- “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.
- the terms "cancer” or “neoplasm” are used to refer to malignancies of the various organ systems, including those affecting the lung, breast, thyroid, lymph glands and lymphoid tissue, gastrointestinal organs, and the genitourinary tract, as well as to adenocarcinomas which are generally considered to include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
- carcinoma is art-recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
- An "adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
- hematopoietic neoplastic disorders refers to diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.
- the diseases arise from poorly differentiated acute leukemias (e.g., erythroblastic leukemia and acute megakaryoblastic leukemia).
- Additional exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit Rev.
- lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM).
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- PLL prolymphocytic leukemia
- HLL hairy cell leukemia
- WM Waldenstrom's macroglobulinemia
- malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Stemberg disease.
- ATL adult T cell leukemia/lymphoma
- CCL cutaneous T cell lymphoma
- LGF large granular lymphocytic leukemia
- Hodgkin's disease Reed-Stemberg disease.
- IL-2 muteins that are partial agonists and antagonists.
- IL-2 muteins that contain one or more mutations that reduces the binding affinity of the IL-2 mutein for IL-2R ⁇ c receptor as compared to wild-type IL-2 (e.g ., human IL-2, SEQ ID NO: 2).
- IL-2R ⁇ c common gamma chain
- Yc common gamma chain
- IL-2Ry IL-2 receptor subunit gamma
- IL-2RG common gamma chain
- ⁇ c common gamma chain
- IL-2R ⁇ c IL-2R ⁇ c
- Yc IL-2Ry
- IL-2 receptor subunit gamma and “IL-2RG” (Genbank accession numbers: NM_000206 and NP_000197 (human) and NM_013563 and NP_038591 (mouse)) all refer to a member of the type I cytokine receptor family that is a cytokine receptor subunit to the receptor complexes for at least six different interleukin receptor including, but not limited to, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors.
- IL-2R ⁇ c interacts with IL-2R ⁇ to form an intermediate affinity IL-2 receptor primarily on memory T cells and natural killer (NK) cells and interacts with IL-2R ⁇ and IL-2R ⁇ to form a high affinity IL-2 receptor on activated T cells and regulator T cells (Tregs).
- NK natural killer
- muteins can function as IL-2 partial agonists or antagonists by attenuating or inhibiting IL-2 ⁇ /IL-2 ⁇ c heterodimerization and signaling upon binding to IL-2R ⁇ on IL-2R ⁇ +/IL-2R ⁇ c + cells (e.g ., resting T cells and natural killer (NK) cells.
- Exemplary subject IL-2 muteins are at least about 50%, at least about 65%, at least about 70%, at least about 80%, at least about 85%, at least about 87%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to wild-type IL-2.
- the mutation can consist of a change in the number or content of amino acid residues.
- the mutant IL-2 can have a greater or a lesser number of amino acid residues than wild-type IL-2.
- an exemplary mutant polypeptide can contain a substitution of one or more amino acid residues that are present in the wild-type IL-2.
- the mutant IL-2 polypeptide can differ from wild-type IL-2 by the addition, deletion, or substitution of a single amino acid residue.
- an IL-2 mutein that includes an amino acid sequence that is at least 95% identical to the reference amino acid sequence SEQ ID NO:2 is a polypeptide that includes a sequence that is identical to the reference sequence except for the inclusion of up to five alterations of the reference amino acid sequence of SEQ ID NO: 2. For example, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- alterations of the reference sequence can occur at the amino (N--) or carboxy (C--) terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- the IL-2 mutein binds IL-2R ⁇ c with an affinity that is at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than wild-type IL-2.
- the binding affinity of IL-2 mutein can also be expressed as 1.2, 1.4, 1.5, 2, 5, 10, 15, 20, 25, 50, 100, 200, 250 or more fold lower affinity for the IL-2 ⁇ c than wild-type IL-2.
- the binding affinity of a subject IL-2 mutein for IL-2 ⁇ c can be measured using any suitable method known in the art.
- Suitable methods for measuring IL-2R ⁇ c binding include, but are not limited to, radioactive ligand binding assays (e.g ., saturation binding, scatchard plot, nonlinear curve fitting programs and competition binding assays); non-radioactive ligand binding assays (e.g ., fluorescence polarization (FP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance assays ( see , e.g ., Drescher et al., Methods Mol Biol 493:323-343 (2009 )); liquid phase ligand binding assays (e.g ., real-time polymerase chain reaction (RT-qPCR), and immunoprecipitation); and solid phase ligand binding assays (e.g ., multiwell plate assays, on-bead ligand binding assays,
- the IL-2 mutein disrupts the association of the IL-2R ⁇ with the IL-2R ⁇ c such that this IL-2R ⁇ /IL-2R ⁇ c interaction is reduced by about 2%, about 5%, about 10%, about 15%, about 20%, about 50%, about 75%, about 90%, about 95% or more relative to wild-type IL-2.
- the one or more mutations reducing the binding affinity of the IL-2 mutein for IL-2R ⁇ c receptor is an amino acid substitution.
- the subject IL-2 mutein consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions as compared to a wild type IL-2 (SEQ ID NO:2).
- the substituted amino acid residue(s) can be, but are not necessarily, conservative substitutions, which typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
- the substitutions are at amino acid residues of IL-2 that contact the IL-2R ⁇ c binding interface.
- the amino acid substitutions are substitutions at one or more amino acid positions of wild type IL-2 selected from positions: 18, 22, 126, and/or 130, numbered in accordance with wild-type hIL-2 ( e.g ., SEQ ID NO: 2).
- the amino acid substitutions that decrease IL-2R ⁇ c receptor binding affinity include amino acid substitutions L18R, Q22E, A126T and/or S130R or combinations thereof.
- the amino acid substitution that decreases IL-2R ⁇ c receptor binding affinity includes Q126T. In other embodiments, the amino acid substitutions that decrease IL-2R ⁇ c receptor binding affinity include L18R and Q22E. In some embodiments, the amino acid substitutions that decrease IL-2R ⁇ c receptor binding affinity include L18R, Q22E, and Q126T. In other embodiments, the amino acid substitutions that decrease IL-2R ⁇ c receptor binding affinity include L18R, Q22E, Q126T and S130R.
- the IL-2 mutein having a reduced binding affinity for IL-2R ⁇ receptor further includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more mutations that increase IL-2R ⁇ binding affinity.
- the terms "IL-2R ⁇ ” and “CD122" both refer to a member of the type I cytokine receptor family that interacts with IL-2R ⁇ c to form an intermediate affinity IL-2 receptor primarily on memory T cells and natural killer (NK) cells and interacts with IL-2R ⁇ and IL-2R ⁇ c to form a high affinity IL-2 receptor on activated T cells and regulator T cells (Tregs).
- IL-2 muteins that have a strong binding affinity IL-2R ⁇ and a weak binding affinity for IL-2R ⁇ c serve as a dominant-negative scaffold to create a "receptor signaling clamp" to block endogenous signaling.
- Such IL-2 muteins would attenuate IL-2R ⁇ - ⁇ c heterodimerization and represent a new class of mechanism-based IL-2 partial agonists and non-signaling (neutral) molecules that functionally act as antagonists by blocking endogenous cytokines and exerting no action of their own ( see schematic in Fig. 1 ).
- the subject IL-2 mutein includes at least one mutation (e.g., a deletion, addition, or substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acid residues) relative to a wild-type IL-2 (e.g ., SEQ ID NO:2), and binds the IL-2R ⁇ with higher affinity than a wild-type IL-2.
- a mutation e.g., a deletion, addition, or substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acid residues
- the IL-2 mutein binds IL-2R ⁇ with an affinity that is at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% greater than wild-type IL-2.
- the binding affinity of IL-2 mutein can also be expressed as 1.2, 1.4, 1.5, 2, 5, 10, 15, 20, 25, 50, 100, 200, 250 or more fold greater affinity for the IL-2R ⁇ than wild-type IL-2. Binding of the subject IL-2 mutein to IL-2R ⁇ can be assessed by any suitable method known to those in the art, including, but not limited to the methods described above.
- the at least one mutations increasing IL-2R ⁇ binding affinity is an amino acid substitution.
- the amino acid substitutions that increase IL-2R ⁇ binding affinity include substitutions at amino acid positions 124, P65, Q74, L80, R81, L85, I86, I89, I92, and/or V93 numbered in accordance with wild-type hIL-2 (SEQ ID NO: 2):
- the substitutions include I24V, P65H, Q74R, Q74 H, Q74N, Q74S, L80F, L80V, R81I, R81T, R81D, L85V, I86V, I89V, I92F, and/or V93I or combinations thereof.
- the substitutions include Q74N, Q74H, Q74S, L80F, L80V, R81D, R81T, L85V, I86V, I89V, and/or I93V or combinations thereof.
- the amino acid substitutions increasing IL-2R ⁇ binding affinity include: L80F, R81D, L85V, I86V and I92F. In some embodiments, the amino acid substitutions that increase IL-2R ⁇ binding affinity include: Q74N, L80F, R81D, L85V, I86V, I89V, and I92F. In some embodiments, the amino acid substitutions that increase IL-2R ⁇ binding affinity include: Q74N, L80V, R81T, L85V, I86V, and I92F. In some embodiments, the amino acid substitutions that increase IL-2R ⁇ binding affinity include: Q74H, L80F, R81D, L85V, I86V and I92F.
- the amino acid substitutions that increase IL-2R ⁇ binding affinity include: Q74S, L80F, R81D, L85V, I86V and I92F. In certain embodiments, the amino acid substitutions that increase IL-2R ⁇ binding affinity include: Q74N, L80F, R81D, L85V, I86V and I92F. In some embodiments, the amino acid substitutions that increase IL-2R ⁇ binding affinity include: Q74S, R81T, L85V, and I92F.
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L80F, R81D, L85V, I86V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, L80F, R81D, L85V, I86V and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, L80F, R81D, L85V, I86V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, L80F, R81D, L85V, I86V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions Q74N, L80F, R81D, L85V, I86V, I89V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N, L80F, R81D, L85V, I86V, I89V, and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N, L80F, R81D, L85V, I86V, I89V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N, L80F, R81D, L85V, I86V, I89V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions Q74N, L80V, R81T, L85V, I86V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N,L80V, R81T, L85V, I86V and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N,L80V, R81T, L85V, I86V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N,L80V, R81T, L85V, I86V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions Q74H, L80F, R81D, L85V, I86V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74H, L80F, R81D, L85V, I86V and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74H, L80F, R81D, L85V, I86V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74H, L80F, R81D, L85V, I86V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions Q74S, L80F, R81D, L85V, I86V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74S, L80F, R81D, L85V, I86V and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74S, L80F, R81D, L85V, I86V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74S, L80F, R81D, L85V, I86V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions Q74N, L80F, R81D, L85V, I86V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N, L80F, R81D, L85V, I86V and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N, L80F, R81D, L85V, I86V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74N, L80F, R81D, L85V, I86V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions Q74S, R81T, L85V, I92F and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22E, Q74S, R81T, L85V, and I92F.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22S, Q74H, R81T, L85V, I92F, and Q126T.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein having a greater binding affinity for IL-2R ⁇ and a reduced binding affinity for IL-2R ⁇ c receptor as compared to wild-type human IL-2 includes the amino acid substitutions L18R, Q22S, Q74H, R81T, L85V, I92F, Q126T, and S130R.
- the IL-2 mutein has the amino acid sequence:
- the subject IL-2 mutein has an amino acid sequence according to the formula: A-P-T-S-S-S-T-K-K-T-Q-L-Q-L-E-H-L-(X 1 ) n -L-D-L-(X 2 ) n --M-(X 3 ) n --L-N-G-I-N-N-Y-K-N-P-K-L-T-R-M-L-T-F-K-F-Y-M-P-K-K-A-T-E-L-K-H-L-Q-C-L-E-E-E-L-K-(X 4 ) n - - L-E-E-V-L-N-L-A-(X 5 ) n - - S-K-N-F-H-(X 6 ) n -(X 7 ) n --P-R-D-(X 8 ) n --(X 9 )
- an amino acid at least at one of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 or X 14 is not a wild-type amino acid.
- an amino acid at least at two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 or X 14 is not a wild-type amino acid.
- the IL-2 mutein has at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% homology with the IL-2 mutein of SEQ ID NO: 50.
- the subject IL-2 muteins that are partial agonists have one or more reduced functions as compared to wild-type IL-2.
- the IL-2 mutein has reduced capabilities to stimulate one or more signaling pathways that are dependent on IL-2R ⁇ /IL-2R ⁇ c heterodimerization. In some embodiments, the subject IL-2 mutein has a reduced capability to stimulate STAT5 phosphorylation in an IL-2R ⁇ + cell as compared to wild-type hIL-2.
- the IL-2 mutein stimulates STAT5 phosphorylation in an IL-2R ⁇ + cell at a level that is 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or less of the level that wild-type IL-2 stimulates STAT5 phosphorylation in the same cell.
- the IL-2R ⁇ + cell is a T cell.
- the T cell is a CD8+ T cell.
- the CD8+ T cell is a freshly isolated CD8+ T cell.
- the CD8+ T cell T cell is an activated CD8+ T cell.
- the IL-2R ⁇ + cell is a natural killer (NK) cell.
- the mutein has a reduced capability to stimulate ERK1/ERK2 signaling in an IL-2R ⁇ + cell as compared to wild-type hIL-2.
- the IL-2 mutein stimulates pERK1/ERK2 signaling in an IL-2R ⁇ + cell at a level that is 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or less of the level that wild-type IL-2 stimulates pERK1/ERK2 signaling in the same cell.
- the IL-2R ⁇ + cell is a T cell.
- the T cell is a CD8+ T cell.
- the CD8+ T cell is a freshly isolated CD8+ T cell.
- the CD8+ T cell T cell is an activated CD8+ T cell.
- the IL-2R ⁇ + cell is a natural killer (NK) cell.
- STAT5 and ERK1/2 signaling can be measure, for example, by phosphorylation of STAT5 and ERK1/2 using any suitable method known in the art.
- STAT5 and ERK1/2 phosphorylation can be measured using antibodies specific for the phosphorylated version of these molecules in combination with flow cytometry analysis as described herein.
- the mutein has a reduced capability to stimulate PI 3-kinase signaling in a IL-2R ⁇ + cell as compared to wild-type hIL-2.
- the IL-2 mutein stimulates PI 3-kinase signaling in an IL-2R ⁇ + cell at a level that is 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or less of the level that wild-type IL-2 stimulates PI 3-kinase signaling in the same cell.
- the IL-2R ⁇ + cell is a T cell.
- the T cell is a CD8+ T cell.
- the CD8+ T cell T cell is an activated CD8+ T cell.
- the IL-2R ⁇ + cell is a natural killer (NK) cell.
- PI 3-kinase signaling can be measured using any suitable method known in the art.
- PI 3-kinase signaling can be measured using antibodies that are specific for phospho-S6 ribosomal protein in conjunction with flow cytometry analysis as described herein.
- the mutein has a reduced capability to induce lymphocyte proliferation as compared to wild-type IL-2.
- the lymphocyte is a T cell.
- the lymphocyte is a primary CD8+ T cell.
- the lymphocyte is an activated CD8+ T cell.
- Cell proliferation can be measured using any suitable method known in the art. For example, lymphocyte proliferation can be measured using a carboxyfluorescein diacetate succinimidyul diester (CFSE) dilution assay or by [ 3 H]-thymidine incorporation, as described herein.
- CFSE carboxyfluorescein diacetate succinimidyul diester
- the IL-2 mutein induce lymphocyte proliferation at a level that is 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or less of the level that wild-type IL-2 induce lymphocyte proliferation.
- the IL-2 mutein has a reduced capability to activate IL-2R ⁇ expression in a lymphocyte as compared to wild-type IL-2.
- the IL-2 mutein activates IL-2R ⁇ expression in a lymphocyte at a level that is 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or less of the level that wild-type IL-2 activates IL-2R ⁇ expression in the same cell.
- the lymphocyte is a CD8+ T cell.
- the CD8+ T cell is a freshly isolated CD8+ T cell.
- the CD8+ T cell is an activated CD8+ T cell.
- IL-2 muteins that exhibit enhanced IL-2R ⁇ binding and decreased IL-2R ⁇ c can function as dominant negative IL-2 antagonists and interfere with one or more IL-2 dependent functions. Such antagonists function by interfering with IL-2 binding to IL-2R ⁇ , while also inhibiting IL-2R ⁇ /IL-2R ⁇ c heterodimerization. Moreover, since IL-15 signaling functions through IL-2R ⁇ /IL-2R ⁇ c receptor binding, it is believed that such IL-2 muteins can also function as IL-15 antagonists. In certain embodiments, the IL-2 mutein inhibits one or more IL-2 and/or IL-15 function.
- the IL-2 mutein that inhibits one or more IL-2 and/or IL-15 functions includes an amino acid substitution at amino acid positions 18, 22, and 126, numbered in accordance with wild-type hIL-2.
- the amino acid substitutions of the IL-2 mutein include L18R, Q22E, and Q126T, numbered in accordance with wild-type hIL-2.
- the IL-2 mutein that inhibits one or more IL-2 and/or IL-15 functions includes an amino acid substitution at amino acid positions 18, 22, 126, and 130 numbered in accordance with wild-type hIL-2.
- the amino acid substitutions of the IL-2 mutein include L18R, Q22E, Q126T and S130R, numbered in accordance with wild-type hIL-2.
- the mutein is an inhibitor of IL-2 and/or IL-15 STAT5 phosphorylation in CD8+ T cells. In some embodiments, the mutein is an inhibitor of IL-2 and/or IL-15 induced proliferation of CD8+ T cells. In some embodiments, the mutein is an inhibitor of IL-2 dependent, TCR-induced cell proliferation.
- IL-2 promotes Th1, Th9, and Treg T cell differentiation and inhibits Th17 differentiation. Therefore, without being bound by any particular theory of operation, it is believed that IL-2 muteins that function as IL-2 antagonists are capable of inhibiting Th1, Th9, and/or Treg cell differentiation or promoting Th17 cell differentiation.
- the IL-2 mutein is an inhibitor of IL-2 dependent Th1, Th9 and/or Treg differentiation. In certain embodiments, the mutein is a promoter of Th17 differentiation.
- the mutein is an inhibitor an inhibitor of IL-2 dependent activation of natural killer (NK) cells.
- IL-2 activation of NK cells can be measured by any suitable method known in the art, for example, by measuring IL-2 induced CD69 expression and/or cytotoxicity, as described herein.
- polypeptides used in the practice of the instant invention are synthetic, or are produced by expression of a recombinant nucleic acid molecule.
- the polypeptide is a chimera (e.g., a fusion protein containing at least a mutant IL-2 polypeptide and a heterologous polypeptide)
- it can be encoded by a hybrid nucleic acid molecule containing one sequence that encodes all or part of the mutant IL-2, and a second sequence that encodes all or part of the heterologous polypeptide.
- subject IL-2 muteins described herein may be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein, or to a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells.
- Methods for constructing a DNA sequence encoding the IL-2 muteins and expressing those sequences in a suitably transformed host include, but are not limited to, using a PCR-assisted mutagenesis technique. Mutations that consist of deletions or additions of amino acid residues to an IL-2 polypeptide can also be made with standard recombinant techniques. In the event of a deletion or addition, the nucleic acid molecule encoding IL-2 is optionally digested with an appropriate restriction endonuclease. The resulting fragment can either be expressed directly or manipulated further by, for example, ligating it to a second fragment.
- the ligation may be facilitated if the two ends of the nucleic acid molecules contain complementary nucleotides that overlap one another, but blunt-ended fragments can also be ligated.
- PCR-generated nucleic acids can also be used to generate various mutant sequences.
- the complete amino acid sequence can be used to construct a back-translated gene.
- a DNA oligomer containing a nucleotide sequence coding for IL-2 mutein can be synthesized.
- several small oligonucleotides coding for portions of the desired polypeptide can be synthesized and then ligated.
- the individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly.
- subject IL-2 muteins can be chemically synthesized. Chemically synthesized polypeptides are routinely generated by those of skill in the art.
- the DNA sequences encoding an IL-2 mutein will be inserted into an expression vector and operatively linked to an expression control sequence appropriate for expression of the IL-2 mutein in the desired transformed host.
- Proper assembly can be confirmed by nucleotide sequencing, restriction mapping, and expression of a biologically active polypeptide in a suitable host.
- the gene in order to obtain high expression levels of a transfected gene in a host, the gene must be operatively linked to transcriptional and translational expression control sequences that are functional in the chosen expression host.
- the DNA sequence encoding the IL-2 mutein can also include DNA sequences that encode a signal sequence.
- Such signal sequence should be one recognized by the cell chosen for expression of the IL-2 mutein. It can be prokaryotic, eukaryotic or a combination of the two. It can also be the signal sequence of native IL-2. The inclusion of a signal sequence depends on whether it is desired to secrete the IL-2 mutein from the recombinant cells in which it is made. If the chosen cells are prokaryotic, it generally is preferred that the DNA sequence not encode a signal sequence. If the chosen cells are eukaryotic, it generally is preferred that a signal sequence be encoded and most preferably that the wild-type IL-2 signal sequence be used.
- exemplary subject IL-2 muteins can be prepared as fusion or chimeric polypeptides that include a subject IL-2 muteins and a heterologous polypeptide (i.e., a polypeptide that is not IL-2 or a mutant thereof) ( see , e.g ., U.S. Pat. No. 6,451,308 ).
- exemplary heterologous polypeptides can increase the circulating half-life of the chimeric polypeptide in vivo , and may, therefore, further enhance the properties of the mutant IL-2 polypeptides.
- the polypeptide that increases the circulating half-life may be a serum albumin, such as human serum albumin, or the Fc region of the IgG subclass of antibodies that lacks the IgG heavy chain variable region.
- exemplary Fc regions can include a mutation that inhibits complement fixation and Fc receptor binding, or it may be lytic, i.e., able to bind complement or to lyse cells via another mechanism, such as antibody-dependent complement lysis (ADCC; USSN 08/355,502 filed Dec. 12, 1994 ).
- the "Fc region” can be a naturally occurring or synthetic polypeptide that is homologous to the IgG C-terminal domain produced by digestion of IgG with papain.
- IgG Fc has a molecular weight of approximately 50 kDa.
- the mutant IL-2 polypeptides can include the entire Fc region, or a smaller portion that retains the ability to extend the circulating half-life of a chimeric polypeptide of which it is a part.
- full-length or fragmented Fc regions can be variants of the wild-type molecule. That is, they can contain mutations that may or may not affect the function of the polypeptides; as described further below, native activity is not necessary or desired in all cases.
- the IL-2 mutein fusion protein e.g. , an IL-2 partial agonist or antagonist as described herein
- the IL-2 mutein fusion protein includes an IgG1, IgG2, IgG3, or IgG4 Fc region.
- the Fc region can be "lytic" or "non-lytic,” but is typically non-lytic.
- a non-lytic Fc region typically lacks a high affinity Fc receptor binding site and a C'1q binding site.
- the high affinity Fc receptor binding site of murine IgG Fc includes the Leu residue at position 235 of IgG Fc.
- the Fc receptor binding site can be destroyed by mutating or deleting Leu 235.
- substitution of Glu for Leu 235 inhibits the ability of the Fc region to bind the high affinity Fc receptor.
- the murine C'1q binding site can be functionally destroyed by mutating or deleting the Glu 318, Lys 320, and Lys 322 residues of IgG.
- a lytic IgG Fc region has a high affinity Fc receptor binding site and a C'1q binding site.
- the high affinity Fc receptor binding site includes the Leu residue at position 235 of IgG Fc
- the C'1q binding site includes the Glu 318, Lys 320, and Lys 322 residues of IgG1.
- Lytic IgG Fc has wild-type residues or conservative amino acid substitutions at these sites.
- Lytic IgG Fc can target cells for antibody dependent cellular cytotoxicity or complement directed cytolysis (CDC). Appropriate mutations for human IgG are also known (see, e.g., Morrison et al., The Immunologist 2:119-124, 1994 ; and Brekke et al., The Immunologist 2: 125, 1994 ).
- the chimeric polypeptide can include a subject IL-2 mutein and a polypeptide that functions as an antigenic tag, such as a FLAG sequence.
- FLAG sequences are recognized by biotinylated, highly specific, anti-FLAG antibodies, as described herein (see also Blanar et al., Science 256:1014, 1992 ; LeClair et al., Proc. Natl. Acad. Sci. USA 89:8145, 1992 ).
- the chimeric polypeptide further comprises a C-terminal c-myc epitope tag.
- the chimeric polypeptide includes the mutant IL-2 polypeptide and a heterologous polypeptide that functions to enhance expression or direct cellular localization of the mutant IL-2 polypeptide, such as the Aga2p agglutinin subunit (see, e.g., Boder and Wittrup, Nature Biotechnol. 15:553-7, 1997 ).
- a chimeric polypeptide including a mutant IL-2 and an antibody or antigen-binding portion thereof can be generated.
- the antibody or antigen-binding component of the chimeric protein can serve as a targeting moiety. For example, it can be used to localize the chimeric protein to a particular subset of cells or target molecule. Methods of generating cytokine-antibody chimeric polypeptides are described, for example, in U.S. Pat. No. 6,617,135 .
- the subject IL-2 mutein either alone or as a part of a chimeric polypeptide, such as those described above, can be obtained by expression of a nucleic acid molecule.
- IL-2 muteins can be described in terms of their identity with wild-type IL-2 polypeptides, the nucleic acid molecules encoding them will necessarily have a certain identity with those that encode wild-type IL-2.
- the nucleic acid molecule encoding a subject IL-2 mutein can be at least 50%, at least 65%, preferably at least 75%, more preferably at least 85%, and most preferably at least 95% (e.g., 99%) identical to the nucleic acid encoding wild-type IL-2 (e.g., SEQ ID NO:2).
- nucleic acid molecules provided can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide.
- These nucleic acid molecules can consist of RNA or DNA (for example, genomic DNA, cDNA, or synthetic DNA, such as that produced by phosphoramidite-based synthesis), or combinations or modifications of the nucleotides within these types of nucleic acids.
- the nucleic acid molecules can be double-stranded or single-stranded (i.e., either a sense or an antisense strand).
- the nucleic acid molecules are not limited to sequences that encode polypeptides; some or all of the non-coding sequences that lie upstream or downstream from a coding sequence (e.g ., the coding sequence of IL-2) can also be included.
- a coding sequence e.g ., the coding sequence of IL-2
- Those of ordinary skill in the art of molecular biology are familiar with routine procedures for isolating nucleic acid molecules. They can, for example, be generated by treatment of genomic DNA with restriction endonucleases, or by performance of the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- the nucleic acid molecule is a ribonucleic acid (RNA) molecules can be produced, for example, by in vitro transcription.
- Exemplary isolated nucleic acid molecules of the present disclosure can include fragments not found as such in the natural state.
- this disclosure encompasses recombinant molecules, such as those in which a nucleic acid sequence (for example, a sequence encoding a mutant IL-2) is incorporated into a vector (e.g., a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location).
- a subject nucleic acid molecule can contain sequences encoding a "marker” or "reporter.”
- marker or reporter genes include ⁇ -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo r , G418 r ), dihydrofolate reductase (DHFR), hygromycin-B-hosphotransferase (HPH), thymidine kinase (TK), lacz (encoding ⁇ -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT).
- CAT chloramphenicol acetyltransferase
- ADA adenosine deaminase
- DHFR dihydrofolate reductase
- HPH hygromycin-B-
- the subject nucleic acid molecules can be obtained by introducing a mutation into IL-2-encoding DNA obtained from any biological cell, such as the cell of a mammal.
- the subject nucleic acids can be those of a mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, baboon, dog, or cat.
- the nucleic acid molecules will be those of a human.
- nucleic acid molecules described above can be contained within a vector that is capable of directing their expression in, for example, a cell that has been transduced with the vector. Accordingly, in addition to the subject IL-2 muteins, expression vectors containing a nucleic acid molecule encoding a subject IL-2 mutein and cells transfected with these vectors are among the preferred embodiments.
- vectors and expression control sequences will function equally well to express the DNA sequences described herein. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation. For example, in selecting a vector, the host must be considered because the vector must replicate in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered.
- vectors that can be used include those that allow the DNA encoding the IL-2 muteins to be amplified in copy number. Such amplifiable vectors are well known in the art.
- DHFR vectors able to be amplified by DHFR amplification
- vectors able to be amplified by DHFR amplification see, e.g. , Kaufman, U.S. Pat. No. 4,470,461 , Kaufman and Sharp, "Construction of a Modular Dihydrafolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression", Mol. Cell. Biol., 2, pp. 1304-19 (1982 )
- GS glutamine synthetase
- the human IL-2 muteins of the present disclosure will be expressed from vectors, preferably expression vectors.
- the vectors are useful for autonomous replication in a host cell or may be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome (e.g., nonepisomal mammalian vectors).
- Expression vectors are capable of directing the expression of coding sequences to which they are operably linked.
- expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors).
- other forms of expression vectors such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses) are included also.
- Exemplary recombinant expression vectors can include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, operably linked to the nucleic acid sequence to be expressed.
- the expression constructs or vectors can be designed for expression of an IL-2 mutein or variant thereof in prokaryotic or eukaryotic host cells.
- Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y .) and other standard molecular biology laboratory manuals.
- the recombinant IL-2 muteins or biologically active variants thereof can also be made in eukaryotes, such as yeast or human cells.
- eukaryotic host cells include insect cells (examples of Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series ( Smith et al. (1983) Mol. Cell Biol. 3:2156-2165 ) and the pVL series ( Lucklow and Summers (1989) Virology 170:31-39 )); yeast cells (examples of vectors for expression in yeast S. cerenvisiae include pYepSec1 ( Baldari et al.
- mammalian expression vectors include pCDM8 ( Seed (1987) Nature 329:840 ) and pMT2PC ( Kaufman et al. (1987) EMBO J. 6:187:195 )).
- Suitable mammalian cells include Chinese hamster ovary cells (CHO) or COS cells.
- the expression vector's control functions are often provided by viral regulatory elements.
- promoters are derived from polyoma, Adenovirus 2, cytomegalovirus, and Simian Virus 40.
- suitable expression systems for both prokaryotic and eukaryotic cells see Chapters 16 and 17 of Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y .). See , Goeddel (1990) in Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, Calif .).
- the sequences encoding the human IL-2 muteins of the present disclosure can be optimized for expression in the host cell of interest.
- the G-C content of the sequence can be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. Methods for codon optimization are well known in the art. Codons within the IL-2 mutein coding sequence can be optimized to enhance expression in the host cell, such that about 1%, about 5%, about 10%, about 25%, about 50%, about 75%, or up to 100% of the codons within the coding sequence have been optimized for expression in a particular host cell.
- Vectors suitable for use include T7-based vectors for use in bacteria (see , for example, Rosenberg et al., Gene 56:125, 1987 ), the pMSXND expression vector for use in mammalian cells ( Lee and Nathans, J. Biol. Chem. 263:3521, 1988 ), and baculovirus-derived vectors (for example, the expression vector pBacPAK9 from Clontech, Palo Alto, Calif.) for use in insect cells.
- T7-based vectors for use in bacteria see , for example, Rosenberg et al., Gene 56:125, 1987
- the pMSXND expression vector for use in mammalian cells
- baculovirus-derived vectors for example, the expression vector pBacPAK9 from Clontech, Palo Alto, Calif.
- nucleic acid inserts which encode the subject IL-2 muteins in such vectors, can be operably linked to a promoter, which is selected based on, for example, the cell type in which expression is sought.
- an expression control sequence a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the actual DNA sequence encoding the subject IL-2 mutein, particularly as regards potential secondary structures. Hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the DNA sequences of this invention, their secretion characteristics, their ability to fold the polypeptides correctly, their fermentation or culture requirements, and the ease of purification of the products coded for by the DNA sequences.
- expression control sequence and expression vector in some embodiments, will depend upon the choice of host.
- a wide variety of expression host/vector combinations can be employed.
- Useful expression vectors for eukaryotic hosts include, for example, vectors with expression control sequences from SV40, bovine papilloma virus, adenovirus and cytomegalovirus.
- Useful expression vectors for bacterial hosts include known bacterial plasmids, such as plasmids from E.
- coli including col El, pCRI, pER32z, pMB9 and their derivatives, wider host range plasmids, such as RP4, phage DNAs, e.g., the numerous derivatives of phage lambda, e.g., NM989, and other DNA phages, such as M13 and filamentous single stranded DNA phages.
- Useful expression vectors for yeast cells include the 2 ⁇ plasmid and derivatives thereof.
- Useful vectors for insect cells include pVL 941 and pFastBacTM 1 (GibcoBRL, Gaithersburg, Md.). Cate et al., "Isolation Of The Bovine And Human Genes For Mullerian Inhibiting Substance And Expression Of The Human Gene In Animal Cells", Cell, 45, pp. 685-98 (1986 ).
- any of a wide variety of expression control sequences can be used in these vectors.
- Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors.
- useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, the major operator and promoter regions of phage lambda, for example PL, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g.
- PhoA the promoters of the yeast a-mating system, the polyhedron promoter of Baculovirus, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
- a T7 promoter can be used in bacteria, a polyhedrin promoter can be used in insect cells, and a cytomegalovirus or metallothionein promoter can be used in mammalian cells. Also, in the case of higher eukaryotes, tissue-specific and cell type-specific promoters are widely available. These promoters are so named for their ability to direct expression of a nucleic acid molecule in a given tissue or cell type within the body. Skilled artisans are well aware of numerous promoters and other regulatory elements which can be used to direct expression of nucleic acids.
- vectors can contain origins of replication, and other genes that encode a selectable marker.
- neomycin-resistance (neo r ) gene imparts G418 resistance to cells in which it is expressed, and thus permits phenotypic selection of the transfected cells.
- Viral vectors that can be used in the invention include, for example, retroviral, adenoviral, and adeno-associated vectors, herpes virus, simian virus 40 (SV40), and bovine papilloma virus vectors ( see , for example, Gluzman (Ed.), Eukaryotic Viral Vectors, CSH Laboratory Press, Cold Spring Harbor, N.Y .).
- a cell of the invention is a transfected cell, i.e., a cell into which a nucleic acid molecule, for example a nucleic acid molecule encoding a mutant IL-2 polypeptide, has been introduced by means of recombinant DNA techniques.
- the progeny of such a cell are also considered within the scope of the invention.
- an IL-2 mutein can be produced in a prokaryotic host, such as the bacterium E. coli, or in a eukaryotic host, such as an insect cell (e.g. , an Sf21 cell), or mammalian cells (e.g ., COS cells, NIH 3T3 cells, or HeLa cells). These cells are available from many sources, including the American Type Culture Collection (Manassas, Va.). In selecting an expression system, it matters only that the components are compatible with one another. Artisans or ordinary skill are able to make such a determination. Furthermore, if guidance is required in selecting an expression system, skilled artisans may consult Ausubel et al. (Current Protocols in Molecular Biology, John Wiley and Sons, New York, N.Y., 1993 ) and Pouwels et al. (Cloning Vectors: A Laboratory Manual, 1985 Suppl. 1987 ).
- the expressed polypeptides can be purified from the expression system using routine biochemical procedures, and can be used, e.g ., as therapeutic agents, as described herein.
- IL-2 muteins obtained will be glycosylated or unglycosylated depending on the host organism used to produce the mutein. If bacteria are chosen as the host then the IL-2 mutein produced will be unglycosylated. Eukaryotic cells, on the other hand, will glycosylate the IL-2 muteins, although perhaps not in the same way as native-IL-2 is glycosylated.
- the IL-2 mutein produced by the transformed host can be purified according to any suitable method. Various methods are known for purifying IL-2. See, e.g. Current Protocols in Protein Science, Vol 2. Eds: John E. Coligan, Ben M. Dunn, Hidde L. Ploehg, David W.
- IL-2 muteins can be isolated from inclusion bodies generated in E. coli, or from conditioned medium from either mammalian or yeast cultures producing a given mutein using cation exchange, gel filtration, and or reverse phase liquid chromatography.
- Another exemplary method of constructing a DNA sequence encoding the IL-2 muteins is by chemical synthesis. This includes direct synthesis of a peptide by chemical means of the protein sequence encoding for an IL-2 mutein exhibiting the properties described. This method can incorporate both natural and unnatural amino acids at positions that affect the interactions of IL-2 with the IL-2R ⁇ , the IL-2R ⁇ and/or the IL-2R ⁇ . Alternatively a gene which encodes the desired IL-2 mutein can be synthesized by chemical means using an oligonucleotide synthesizer.
- Such oligonucleotides are designed based on the amino acid sequence of the desired IL-2 mutein, and preferably selecting those codons that are favored in the host cell in which the recombinant mutein will be produced.
- the genetic code is degenerate-that an amino acid may be coded for by more than one codon.
- Phe (F) is coded for by two codons
- TIC or TTT is coded for by TAC or TAT
- his (H) is coded for by CAC or CAT.
- Trp (W) is coded for by a single codon, TGG.
- degenerate variants thereof in the context of this invention means all DNA sequences that code for and thereby enable expression of a particular mutein.
- the biological activity of the IL-2 muteins can be assayed by any suitable method known in the art.
- Such assays include PHA-blast proliferation and NK cell proliferation.
- subject IL-2 muteins, and/or nucleic acids expressing them can be administered to a subject to treat a disorder associated with abnormal apoptosis or a differentiative process (e.g., cellular proliferative disorders or cellular differentiative disorders, such as cancer, by, for example, producing an active or passive immunity).
- a disorder associated with abnormal apoptosis or a differentiative process e.g., cellular proliferative disorders or cellular differentiative disorders, such as cancer, by, for example, producing an active or passive immunity.
- the disclosed IL-2 muteins may possess advantageous properties, such as reduced vascular leak syndrome.
- Examples of cellular proliferative and/or differentiative disorders include cancer (e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias).
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver.
- the compositions of the present invention e.g., mutant IL-2 polypeptides and/or the nucleic acid molecules that encode them
- the mutant IL-2 polypeptides can be used to treat patients who have, who are suspected of having, or who may be at high risk for developing any type of cancer, including renal carcinoma or melanoma, or any viral disease.
- Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
- the term also includes carcinosarcomas, which include malignant tumors composed of carcinomatous and sarcomatous tissues.
- proliferative disorders include hematopoietic neoplastic disorders.
- the skin disorder may involve the aberrant activity of a cell or a group of cells or layers in the dermal, epidermal, or hypodermal layer, or an abnormality in the dermal-epidermal junction.
- the skin disorder may involve aberrant activity of keratinocytes (e.g., hyperproliferative basal and immediately suprabasal keratinocytes), melanocytes, Langerhans cells, Merkel cells, immune cell, and other cells found in one or more of the epidermal layers, e.g., the stratum basale (stratum germinativum), stratum spinosum, stratum granulosum, stratum lucidum or stratum corneum.
- stratum basale stratum germinativum
- stratum spinosum stratum granulosum
- the disorder may involve aberrant activity of a dermal cell, for example, a dermal endothelial, fibroblast, immune cell (e.g., mast cell or macrophage) found in a dermal layer, for example, the papillary layer or the reticular layer.
- a dermal cell for example, a dermal endothelial, fibroblast, immune cell (e.g., mast cell or macrophage) found in a dermal layer, for example, the papillary layer or the reticular layer.
- Examples of skin disorders include psoriasis, psoriatic arthritis, dermatitis (eczema), for example, exfoliative dermatitis or atopic dermatitis, pityriasis rubra pilaris, pityriasis rosacea, parapsoriasis, pityriasis lichenoiders, lichen planus, lichen nitidus, ichthyosiform dermatosis, keratodermas, dermatosis, alopecia areata, pyoderma gangrenosum, vitiligo, pemphigoid (e.g., ocular cicatricial pemphigoid or bullous pemphigoid), urticaria, prokeratosis, rheumatoid arthritis that involves hyperproliferation and inflammation of epithelial-related cells lining the joint capsule; dermatitises such as seborr
- psoriasis is intended to have its medical meaning, namely, a disease which afflicts primarily the skin and produces raised, thickened, scaling, nonscarring lesions.
- the lesions are usually sharply demarcated erythematous papules covered with overlapping shiny scales.
- the scales are typically silvery or slightly opalescent. Involvement of the nails frequently occurs resulting in pitting, separation of the nail, thickening and discoloration.
- Psoriasis is sometimes associated with arthritis, and it may be crippling.
- Hyperproliferation of keratinocytes is a key feature of psoriatic epidermal hyperplasia along with epidermal inflammation and reduced differentiation of keratinocytes. Multiple mechanisms have been invoked to explain the keratinocyte hyperproliferation that characterizes psoriasis. Disordered cellular immunity has also been implicated in the pathogenesis of psoriasis.
- psoriatic disorders include chronic stationary psoriasis, psoriasis vulgaris, eruptive (gluttate) psoriasis, psoriatic erythroderma, generalized pustular psoriasis (Von Zumbusch), annular pustular psoriasis, and localized pustular psoriasis.
- mutant IL-2 polypeptides can be used in ex vivo methods.
- cells e.g., peripheral blood lymphocytes or purified populations of lymhocytes isolated from a patient and placed or maintained in culture
- the contacting step can be affected by adding the IL-2 mutant to the culture medium.
- the culture step can include further steps in which the cells are stimulated or treated with other agents, e.g., to stimulate proliferation, or to expand a population of cells that is reactive to an antigen of interest (e.g., a cancer antigen or a viral antigen).
- an antigen of interest e.g., a cancer antigen or a viral antigen
- the subject IL-2 mutein that function as IL-2 antagonists described herein are useful for the treatment of one or more conditions wherein suppression of one or more IL-2 and/or IL-15 dependent functions is useful.
- the IL-2 mutein antagonists described herein is used for the treatment of one or more diseases or conditions wherein suppression of IL-2R ⁇ /IL-2R ⁇ heterodimerization and downstream signaling is useful (e.g ., GVDH or leukemia).
- the method of treatment is for the treatment of graft versus host disease (GVHD).
- the treatment includes the step of administering to a subject having GVHD a therapeutically effective amount of an IL-2 mutein that is an IL-2 antagonist.
- IL-2 and IL-15 is known to contribute to GVHD (( Ferrara et al., Journal of Immunology 137: 1874 (1986 ); and Blaser et al., Blood 105: 894 (2005 )). Therefore, without being bound by any particular theory of operation, it is believed that the IL-2 antagonists described herein are useful for the treatment of GVHD.
- the IL-2 mutein for the treatment of GVHD includes one or more mutations that reduces its binding to IL-2R ⁇ c receptor as compared to wild type IL-2 (e.g ., any one of the mutations that reduces IL-2R ⁇ c receptor binding as described herein).
- the mutations that decrease IL-2R ⁇ c receptor binding affinity include the amino acid substitutions L18R, Q22E, Q126T and S130R.
- the IL-2 mutein further with decreased IL-2R ⁇ c receptor binding affinity further includes one or more amino acid mutations that increase the IL-2 muteins binding affinity for IL-2R ⁇ , as compared to wild-type IL-2 (e.g., any one of the mutations that increase IL-2R ⁇ binding as described herein).
- the IL-2 mutein further includes the amino acid substitutions L80F, R81D, L85V, I86V and I92F.
- the IL-2 mutein includes the amino acid substitutions L18R, Q22E, L80F, R81D, L85V, Q126T, S130R, I86V and I92F.
- the method of treatment is for the treatment of an IL-2 and/or IL-15 mediated leukemia.
- the leukemia is adult T-cell leukemia (ATL).
- ATL is characterized by a malignant expansion of CD4+ T cells that exhibit an early growth phase that involves autocrine signals by IL-2 and IL-15 as well as paracrine signals by IL-9.
- IL-2 partial agonists and antagonists can be used to treat such forms of leukemia.
- the treatment includes the step of administering to a subject having adult T-cell leukemia a therapeutically effective amount of an IL-2 mutein that is an IL-2 antagonist.
- the patient has chronic and smoldering ATL.
- the IL-2 mutein for the treatment of ATL includes one or more mutations that reduces its binding to IL-2R ⁇ c receptor as compared to wild type IL-2 ( e.g. , any one of the mutations that reduces IL-2R ⁇ c receptor binding as described herein).
- the mutations that decrease IL-2R ⁇ c receptor binding affinity include the amino acid substitutions L18R, Q22E, Q126T and S130R.
- the IL-2 mutein further with decreased IL-2R ⁇ c receptor binding affinity further includes one or more amino acid mutations that increase the IL-2 muteins binding affinity for IL-2R ⁇ , as compared to wild-type IL-2 ( e.g ., any one of the mutations that increase IL-2R ⁇ binding as described herein).
- the IL-2 mutein further includes the amino acid substitutions L80F, R81D, L85V, I86V and I92F.
- the IL-2 mutein includes the amino acid substitutions L18R, Q22E, L80F, R81D, L85V, Q126T, S130R, I86V and I92F.
- subject IL-2 muteins and nucleic acids can be incorporated into compositions, including pharmaceutical compositions.
- Such compositions typically include the polypeptide or nucleic acid molecule and a pharmaceutically acceptable carrier.
- a pharmaceutical composition is formulated to be compatible with its intended route of administration.
- the mutant IL-2 polypeptides of the invention may be given orally, but it is more likely that they will be administered through a parenteral route.
- parenteral routes of administration include, for example, intravenous, intradermal, subcutaneous, transdermal (topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
- antibacterial agents such as benzyl alcohol or methyl parabens
- antioxidants such as ascorbic acid or sodium bisulfite
- chelating agents such as ethylenediaminetetraacetic
- pH can be adjusted with acids or bases, such as mono- and/or dibasic sodium phosphate, hydrochloric acid or sodium hydroxide (e.g ., to a pH of about 7.2-7.8, e.g ., 7.5).
- acids or bases such as mono- and/or dibasic sodium phosphate, hydrochloric acid or sodium hydroxide (e.g ., to a pH of about 7.2-7.8, e.g ., 7.5).
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM. (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants, e.g., sodium dodecyl sulfate.
- surfactants e.g., sodium dodecyl sulfate.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions if used, generally include an inert diluent or an edible carrier.
- the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, PrimogelTM, or corn starch; a lubricant such as magnesium stearate or SterotesTM; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, PrimogelTM, or corn starch
- a lubricant such as magnesium stearate or SterotesTM
- a glidant such as colloidal silicon dioxide
- subject IL-2 muteins or the nucleic acids encoding them, are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration of the subject IL-2 muteins or nucleic acids can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- compounds can also be administered by transfection or infection using methods known in the art, including but not limited to the methods described in McCaffrey et al. (Nature 418:6893, 2002 ), Xia et al. (Nature Biotechnol. 20: 1006-1010, 2002 ), or Putnam (Am. J. Health Syst. Pharm. 53: 151-160, 1996 , erratum at Am. J. Health Syst. Pharm. 53:325, 1996 ).
- the subject IL-2 muteins or nucleic acids are prepared with carriers that will protect the mutant IL-2 polypeptides against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
- Such formulations can be prepared using standard techniques.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 .
- Dosage, toxicity and therapeutic efficacy of such subject IL-2 muteins or nucleic acids compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
- Compounds that exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC 50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- a therapeutically effective amount of a subject IL-2 mutein depends on the polypeptide selected. For instance, single dose amounts in the range of approximately 0.001 to 0.1 mg/kg of patient body weight can be administered; in some embodiments, about 0.005, 0.01, 0.05 mg/kg may be administered. In some embodiments, 600,000 IU/kg is administered (IU can be determined by a lymphocyte proliferation bioassay and is expressed in International Units (IU) as established by the World Health Organization 1 st International Standard for Interleukin-2 (human)). The dosage may be similar to, but is expected to be less than, that prescribed for PROLEUKIN®.
- compositions can be administered one from one or more times per day to one or more times per week; including once every other day.
- treatment of a subject with a therapeutically effective amount of the subject IL-2 muteins can include a single treatment or, can include a series of treatments.
- the compositions are administered every 8 hours for five days, followed by a rest period of 2 to 14 days, e.g., 9 days, followed by an additional five days of administration every 8 hours.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- Example 1 Functional Expression of IL-2 on the Surface of Yeast
- IL-2 has been displayed on bacteriophage previously ( Buchli et al., Arch. Biochem. Biophys. 339:79-84, 1997 ), the prior system was not amenable to directed evolution and therefore not suitable for obtaining IL-2 mutants with improved binding for subunits of the IL-2R.
- IL-2 was expressed on the surface of yeast cells. Human IL-2 DNA was cloned into yeast display vector pCT302. Saccharomyces cerevisiae strain EBY100 was transformed with the pCT302_IL-2 vector and grown for 3 days at 30°C on SD-CAA plates.
- IL-2 yeast Individual colonies of IL-2 yeast were grown overnight at 30°C in SD-CAA, then introduced in SGCAA for 2 days at 20°C. The yeast were stained with tetramerized biotinylated IL-2R ⁇ , biotinylated ⁇ or biotinylated IL-2R ⁇ in the presence of biotinylated ⁇ .
- the ectodomains of IL-2R ⁇ and ⁇ were C-terminally biotinylated and coupled to phycoerythrin-conjugaed strepavidin for use as a staining and sorting reagent.
- IL-2 R ⁇ tetramers were formed by incubating 2 ⁇ M of biotinylated IL-2R ⁇ with 470nM streptavidin-phycoerythrin (SA-PE, Invitrogen) for 15 minutes on ice. These receptor "tetramers" enhanced the avidity of the low affinity monomeric ectodomain (ECD) interactions with IL-2, enabling maximal recovery of IL-2 variants from libraries. Similar to solution wild-type IL-2, yeast-displayed IL-2 bound weakly to IL- 2R ⁇ alone, did not bind to at all to ⁇ alone, but did bind to ⁇ in the presence of IL- 2R ⁇ , as evidenced by diagonal staining seen by flow cytometry (data not shown). Thus, the yeast-displayed IL-2 recapitulates the cooperative assembly of the heterodimeric receptor complex on cells seen with soluble IL-2, and is therefore suitable as a platform for library selection.
- SA-PE streptavidin-phycoerythrin
- the first generation in vitro strategy was to create an error-prone PCR library of the entire IL-2 gene.
- the first generation mutant IL-2 library was constructed as follows. Wildtype human interleukin-2 (IL-2) was subjected to error-prone mutagenesis using the GeneMorph® II Random Mutagenesis kit following the manufacturer's instructions. The following primers were used for error-prone PCR: 5'-GCACCTACTTCAAGTTCTAC-3' ("IL-2_errprone_for) and 5'-GCCACCAGAGGATCC-3' ("IL-2_errprone_rev). The product of the error prone PCR reaction was then amplified using the following primers: and to yield approximately 130 ⁇ g of DNA.
- Yeast display vector pCT302 was double digested with restriction enzymes NheI and BamHI and gel purified. The IL-2 DNA and the pCT302 DNA were mixed together in a 5:1 ⁇ g ratio with electrocompetent EBY100 yeast. The yeast were electroporated to facilitate entry of the library DNA into the yeast. This electroporation was repeated approximately 20 times to yield a final library size of 1x10 8 transformants.
- first generation IL-2 library The library was subjected to six rounds of selection against IL-2R ⁇ ( Figure 2A ).
- the library was labeled with 470 nM tetrameric IL-2R ⁇ , which was formed by mixing 2 ⁇ M biotinylated IL-2R ⁇ with 470 nM streptavidin-phycoerythrin conjugate (SAV-PE) for 15 min.
- SAV-PE streptavidin-phycoerythrin conjugate
- the library was incubated with IL-2R ⁇ for 1.5 h, washed with PBS-BSA buffer (phosphate buffered saline + bovine serum albumin), and incubated with Miltenyi anti-PE MicroBeads for 20 min at 4°C.
- the cells were again washed and flowed over a magnetic column for selection. This selection method was successively repeated five more times with alterations only in IL-2R ⁇ concentration (round 2 - 1 ⁇ M, round 3 - 1 ⁇ M, round 4 - 300 nM, round 5 - 300 nM, round 6 - 100 nM, all monomeric IL-2R ⁇ ).
- round five and round six yeast cultures were spread on SD-CAA plates, which yielded individual yeast colonies. Eighteen resulting yeast colonies were tested for binding to 500 nM IL-2R ⁇ .
- the IL-2 DNA isolated from these eighteen yeast colonies was sequenced. Amino acid differences among these eighteen yeast colonies relative to the corresponding residue in wildtype IL-2 is shown in Table 1.
- Second generation IL-2 library Based on the high percentage of clones containing L85V, a second IL-2 library was constructed that focused primarily on hydrophobic core residues.
- a site-directed IL-2 library was constructed with mutations at Q74, L80, R81, L85, I86, I89, I92, V93.
- Q74 was allowed to vary as H/K/N/Q/R/S.
- R81 was allowed to vary at all 20 amino acids with the NNK degenerate codon, where N represents a 25% mix each of adenine, thymine, guanine, and cytosine nucleotides and K is either guanine or thymine.
- the remaining residues were allowed to vary as F/I/L/V.
- the library was constructed by assembly PCR using the following oligos:
- the site-directed PCR was amplified with the following oligos:
- PCR amplification oligos (including 50 bp homology )
- the PCR yielded 40 ⁇ g of DNA, which was mixed with double digested pCT302 and electrocompetent EBY100 yeast and electroporated as with the first generation library.
- Second generation IL-2 library The library was subjected to five rounds of selection against IL-2R ⁇ ( Figure 2B ). This selection method was performed exactly as with the first generation library, only with modifications to the concentrations of IL-2R ⁇ used (round 1 - 1 ⁇ M, round 2 - 100 nM, round 3 - 30 nM, round 4 - 30 nM, round 5 - 10 nM, all monomeric IL-2R ⁇ ). Upon conclusion of selections, round four and round five yeast cultures were spread on SD-CAA plates, which yielded individual yeast colonies. 48 individual yeast clones from both rounds were grown in 96-well block format and screened by labeling with 5 nM IL-2R ⁇ and then SAV-PE.
- the screen yielded seven high affinity binders to IL-2R ⁇ ( Figure 3 and Table 2). Amino acid differences among these seven high affinity binders relative to the corresponding residue in wildtype IL-2 is shown in Table 2 along with the binding affinity for IL-2R ⁇ .
- Human IL-2 variants (amino acids 1-133), the IL-2R ⁇ ectodomain (amino acids 1-214), and ⁇ c (amino acids 34-232) were cloned into the pAcGP67-A vector (BD Biosciences) in frame with an N-terminal gp67 signal sequence and C-terminal hexahistidine tag and produced using the baculovirus expression system.
- Baculovirus stocks were prepared by transfection and amplification in Spodoptera frugiperda (Sf9) cells grown in SF900II media (Invitrogen), and protein expression was carried out in suspension Trichoplusia ni (High FiveTM) cells grown in BioWhittaker® Insect XPRESSTM media (Lonza). Proteins were expressed and captured from High FiveTM supernatants after 48-60 hr by nickel agarose (QIAGEN), concentrated and purified by size exclusion chromatography on a SuperdexTM 200 column (GE Healthcare), equilibrated in 10 mM HEPES (pH 7.2) and 150 mM NaCl.
- IL-2 variants used in SPR and cell based assays were expressed fully glycoslylated.
- IL-2R ⁇ and ⁇ c were cloned into the pAcGP67-A vector with a C-terminal biotin acceptor peptide ( BAP )-LNDIFEAQKIEWHE and hexahistidine tag.
- BAP C-terminal biotin acceptor peptide
- Receptor proteins were coexpressed with BirA ligase with excess biotin (100 uM).
- Example 4 Stimulation of CD25 - and CD25 + Natural Killer (YT-1) Cells
- YT-1 and CD25+ YT-1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, minimum non-essential amino acids, sodium pyruvate, 25 mM HEPES, and penicillin-streptomycin (Gibco).
- CD25 + YT-1 cells were purified as follows: 1x10 7 cells were washed with FACS buffer (phosphate buffered saline + 2% bovine serum albumin) and stained with PE-conjugated anti-human CD25 (1:20; Biolegend, San Diego, CA) in 1 mL FACS buffer for 20 minutes at 4 °C.
- the stained cells were labeled with paramagnetic microbeads coupled to anti-PE IgG and separated with an LS MACS® separation column according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Eluted cells were re-suspended in complete RPMI medium at a concentration of 1x10 5 cells and expanded for subsequent experiments. Enrichment of cells was monitored via flow cytometry with the FL-2 channel using an Accuri® C6 flow cytometer.
- CD25 + or CD25 - YT-1 cells were washed with FACS buffer and re-suspended in 200 ⁇ L FACS buffer with the indicated concentration of wild-type, 6-6, H9, or D10 in a 96 well plate. Cells were stimulated for 20 minutes at room temperature and then fixed by addition of formaldehyde to 1.5% and incubated for 10 min. Cells were permeabilized with 100% ice-cold methanol for 20 min on ice, followed by incubation at -80 °C overnight.
- Example 5 Stimulation of CD25- and CD25+ T cells
- Human and mouse CD4 T cells were prepared from PBMC (Stanford Blood Bank) and spleens and lymph nodes of BALB/C mice, respectively using antibody-coated CD4 T cell isolation magnetic beads (Stem Cell Technologies and Miltenyi Biotec). For naive cell stimulation assays, cells were used immediately. For generation of in vitro 'experienced' T cells, wells were pre-coated with secondary antibody (Vector Labs) in bicarbonate buffer, pH 9.6 prior to coating plates with anti-CD3 (OKT3 for human, 2C11 for mouse, eBiosciences) at 100ng/mL.
- T cells were seeded at 0.1x10 6 cells/well with soluble anti-CD28 (CD28.2 for human, 37.51 for mouse, eBiosciences). Cell were cultured for 3 days with full TCR stimulated, followed by 2 days rest in conditioned media and 2 days rest in fresh culture media. Prior to use, live cells were collected by Lympholyte-M (Cederlane) centrifugation and counted.
- soluble anti-CD28 CD28.2 for human, 37.51 for mouse, eBiosciences
- the activity of IL-2 muteins on T cells that were either deficient in CD25 expression or expressed CD25 was assessed ( Figure 6 ).
- the dose response relationship of wild-type IL-2 and six IL-2 muteins were assayed for STAT5 phosphorylation at a protein concentration range of 1ng/ml to 1000 ng/ml.
- the ability of the IL-2 muteins to stimulate STAT5 phosphorylation in CD25 deficient T cells correlated well with their affinity for the IL-2R ⁇ .
- the increase in STAT5 phosphorylation by the IL-2 muteins was two orders of magnitude greater that IL-2.
- Wildtype IL-2 resulted in 48% pSTAT5 stimulation, and the IL-2 muteins yielded between 65-79% pSTAT5 stimulation. Therefore, the IL-2 muteins apparently stimulate experienced human T cells better than wildtype IL-2 but the enhancement is not as pronounced as on cells lacking CD25
- D10 IL-2 mutein on Natural Killer cell function, specifically spontaneous and antibody-dependent cell-mediated cytotoxicity (ADCC) using an EGFR (endothelial growth factor receptor)-expressing squamous tumor cell line (SCC6) and the EGFR monoclonal antibody, cetuximab was assessed.
- EGFR endothelial growth factor receptor
- cetuximab human EGFR-positive squamous cell carcinoma cell line, SCC6, was obtained as a gift from the J. Sunwoo Laboratory (Stanford, CA).
- SCC6 cell line was cultured in DMEM/F12 medium (Invitrogen Life Technologies) supplemented with 10% heat-inactivated FCS (HyClone Laboratories), 100 U/mL penicillin and 100 ⁇ g/mL streptomycin (both from Invitrogen Life Technologies). Cells were grown adherent in culture at 37°C in 5% CO 2 .
- Cetuximab mouse chimeric IgG1 anti-human epidermal growth factor receptor-EGFR; IMC-C225; Erbitux® was obtained from Bristol-Myers Squibb.
- NK cells were isolated from a healthy donor leukocyte-reduced system (LRS) product containing approximately 1x10 9 cells. NK cells were isolated by negative magnetic cell sorting using NK cell isolation beads (Miltenyi Biotec) according to manufacturer's instructions. NK cells were assessed for purity (>90% purity as defined by CD3 - CD56 + flow cytometry). SCC6 target cells were labeled with 150 ⁇ Ci 51 Cr per 1x10 6 cells for 2 h.
- LRS leukocyte-reduced system
- Percent lysis was determined after 5 h cultures of purified NK cells at variable effector:target cell ratios of 0:1, 1:1, and 5:1 with 51 Cr-labeled SCC6 cells in media alone, cetuximab (100 pg/mL), IL-2 (1000 IU/mL), IL-2 D10 (1 pg/mL), IL-2 D10 (10 pg/mL), or combinations including cetuximab (100 pg/mL) plus IL-2(1000 IU/mL), cetuximab (100 pg/mL) plus IL-2 D10 (1 pg/mL), or cetuximab (100 pg/mL) plus IL-2 D10 (10 pg/mL).
- Example 7 IL-2 muteins result in enhanced memory phenotype expansion with relatively low stimulation of suppressor-type T cells (Tregs)
- mice received either PBS, 20 ⁇ g IL-2, 20 ⁇ g H9, or 1.5 ⁇ g IL-2/anti-IL-2 monoclonal antibody complexes and total cell counts of splenic CD3 + CD4 + CD44 high memory phenotype T cells were assessed by flow cytometry.
- IL-2 treatment can lead to severe adverse effects, such as acute pulmonary edema, which is currently a limitation preventing more effective use of IL-2. Accordingly, the toxicity of the disclosed IL-2 muteins relative to IL-2 was assessed ( Figure 11A ).
- C57Bl/6 mice received daily intraperitoneal injections of PBS, 20 ⁇ g IL-2, 20 ⁇ g H9, or 1.5 ⁇ g IL-2/anti-IL-2 monoclonal antibody complexes for 5 consecutive days. 6 days after adoptive cell transfer, the lungs were removed and weighed before and after drying overnight at 58°C under vacuum. Pulmonary wet weight was calculated by subtracting initial pulmonary weight from lung weight after dehydration.
- Example 9 Increased anti-tumor activity of IL-2 muteins in vivo
- the potency of the disclosed IL-2 muteins against tumor cells was tested in vivo. 10 6 B16F10 melanoma cells in 100 ⁇ l RPMI were injected into the upper dermis in the back of mice (3-4 mice per group). Treatment consisted of five daily injections of either PBS, 20 ⁇ g IL-2, 20 ⁇ g H9, or 1.5 ⁇ g IL-2/anti-IL-2 monoclonal antibody complexes (IL-2/mAb) and was started one day after tumor nodules were clearly visible and palpable at a size of ⁇ 15mm 2 . The disclosed IL-2 mutein resulted in enhanced anti-tumor activity in vivo as demonstrated in Figure 11B .
- Example 10 Structural Comparison of IL-2 muteins and IL-2
- IL-2 muteins were recombinantly expressed in order to measure their binding affinity and kinetics for IL-2R ⁇ by surface plasmon resonance (SPR).
- the IL-2 muteins clustered into low, medium, and high affinity classes.
- the low affinity IL-2 muteins (5-2 and 6-6) bound IL-2R ⁇ with K D between 50 and 70 nM, respectively, an affinity gain of 4-6 fold from wild-type IL-2 almost entirely through the L85V substitution.
- the medium and high affinity mutants selected from the secondary, site-directed library had K D 's of 10-15 nM (C5, H4), and 1.2-1.7 nM (B1, D10, E10, G8, H9), respectively.
- the affinity increases were uniformly manifested in reductions in off-rate, and the high affinity IL-2 muteins contained a consensus sequence in the randomized positions of L80F/R81D/L85V/I86V/I92F.
- the D10 mutein as well as the ternary complex of D10 bound to IL-2R ⁇ and ⁇ c were crystallized.
- the structure of D10 alone five of the six mutations are clustered on the B-C loop and within the C helix core, in positions that do not contact IL-2R ⁇ .
- the B-C helix linker region is well-ordered in the electron density map ( Figure 9 ), compared to other IL-2 structures where this region is either partially or completely disordered.
- a low-resolution (3.8 ⁇ ) structure of the D10 ternary receptor complex was also determined to assess whether the mutations have perturbed the IL-2R ⁇ / ⁇ c receptor docking geometry.
- a stable ternary complex of D10 and IL-2R ⁇ was crystallized and purified in the absence of CD25.
- the overall IL-2R ⁇ / ⁇ c heterodimeric architecture and mode of cytokine/IL-2R ⁇ contact in the D10 ternary complex is essentially identical to the previously reported quaternary assembly.
- the potency increase of super-2 is not due to a structural change in receptor dimer architecture, but is likely due to the affinity enhancement.
- the C-helix of IL-2 appears to undergo subtle repositioining upon binding to IL-2R ⁇ , as seen in both the binary and quaternary complexes.
- inspection of three wild-type unliganded structures in the PDB database reveals variability in the C-helix position, consistent with higher B-factors in this helix relative to the rest of the molecule.
- Comparison of the structure of D10 to that of an unliganded IL-2, and IL-2 in the receptor complexes was undertaken. It was observed that the C-helix in D10 is more similar to that seen in the two receptor-bound conformations of IL-2 than the free forms, having undergone a shift up and into the helical core.
- MSM Markov state model
- IL-2 muteins most populated state has an equilibrium probability of ⁇ 0.20, compared to ⁇ 0.05 for IL-2.
- Helix B, the B-C loop, and helix C are rigidified in the IL-2 mutein compared to IL-2.
- the evolved mutations reside on the B-C loop (H74, D81), and within the B and C helix packing interface (F80, V85, V86), both helices - not just helix C - benefit from the mutations and undergo a collective stabilization.
- F92 appears to act as a molecular wedge between helix C and helix A, acting as an additional stabilizing influence at the more C-terminal end of the helix.
- IL-2R ⁇ binds to IL-2 primarily on the B helix and part of the D helix.
- the MD simulations suggest the possibility that binding of IL-2R ⁇ to IL-2 may rigidify helix B, and this structural stabilization may be propagated to the B-C loop and helix C. Similar, in principle, to the apparent effect of the evolved mutations in the IL-2 mutein.
- IL-2 "superkines” with augmented action due to enhanced binding affinity for IL-2R ⁇ were previously developed ( Levin et al., Nature 484: 529 (2012 )). It was hypothesized that this high-affinity superkine/IL-2R ⁇ complex could serve as a dominant-negative scaffold to create a "receptor signaling clamp" to block endogenous signaling.
- H9 variants CD25 + and CD25 - subpopulations of NK-like YT-1 cells were purified and signaling was quantified.
- the H9 mutants behaved as IL-2 partial agonists, producing a range of signaling efficacies from ⁇ 90% down to ⁇ 10% of the wild-type E max (maximum possible effect) level of phosphorylation of STAT5 ( Figure 13A ), with the level of activity for each analogue inversely correlating with the degree of mutation at the ⁇ c interface.
- the signaling potency was relatively independent of IL-2R ⁇ , as demonstrated by the relative E max values for H9-RET and H9-RETR on CD25 + ( Figure 13B ) versus CD25 - ( Figure 13C ) YT-1 cells, suggesting that altered binding to IL-2R ⁇ and ⁇ c was primarily responsible for the behavior of the H9 variants.
- H9-RET and H9-RETR also exhibited diminished induction of other IL-2 signaling pathways, including pERK1/ERK2 in CD25 + YT-1 cells ( Figure 14A ).
- receptor internalization is a key event in signaling
- surface expression of IL-2R ⁇ and IL-2R ⁇ in YT-1 cells in response to the IL-2 variants were also evaluated.
- both H9-RET and H9-RETR drove rapid and complete IL-2R ⁇ internalization ( Figure 13B ), but these partial agonists were much less efficient at promoting internalization of ⁇ c ( Figure 13C ), consistent with their diminished binding to ⁇ c .
- variably disrupting the ⁇ c -binding interface of H9 can yield a variety of IL-2 partial agonists, potentially with an extensive repertoire of signaling efficacies.
- H9-RET could induce weak/partial phosphorylation of STAT5 ( Figure 13E , lower right panel; Figure 13F , lower panel; Figure 13G ), and of S6 ribosomal protein ( Figure 13H ), a member of the PI 3-kinase signaling pathway)), whereas H9-RETR remained essentially inert.
- H9-T significantly induced pSTAT5 in freshly isolated CD8 + T cells ( Figure 13E , upper right panel), and this was markedly increased in pre-activated T cells, albeit still not up to levels observed with IL-2, H9, or H9-RE ( Figure 13E , lower right panel and Figure 13G ).
- H9-T and H9-RET exhibited intermediate activities reminiscent of true partial agonists.
- H9-RET and H9-RETR Given the weak pSTAT5 expression induced by H9-RET and H9-RETR, the effects of these molecules on lymphocyte proliferation were further investigated. Whereas IL-2 and H9 strongly induced proliferation of primary CD8 + T cells and H9-T was intermediate in its effects, neither H9-RET nor H9-RETR induced proliferation of these cells as assessed by carboxyfluorescein diacetate succinimidyl diester (CFSE) dilution ( Figure 15 ) or by [ 3 H]-thymidine incorporation ( Figure 16A , upper panel).
- CFSE carboxyfluorescein diacetate succinimidyl diester
- H9-RETR still had no effect, but H9-RET reproducibly induced proliferation ( Figure 16B , lower panel), revealing that H9-RET can induce different functional outcomes in distinct cell subsets, consistent with the differential effects of H9-RET on pSTAT5 in freshly isolated versus pre-activated CD8 + T cells ( Figure 13E ).
- IL-2 and H9 could potently induce IL-2R ⁇ expression in pre-activated CD8 + T cells, and H9-T was intermediate in its level of IL-2R ⁇ induction, whereas H9-RET and H9-RETR significantly decreased IL-2R ⁇ expression, actually to below the control level, presumably reflecting their potent competition with endogenous IL-2 ( Figure 17 ).
- RNA-Seq was next used to further elucidate the basis for the weak actions of H9-RET and H9-RETR in pre-activated CD8 + T cells ( Figure 16 , B and C).
- IL-2 and H9 induced genes that control cell cycle or are involved in cytokine signaling (e.g. CCND2 , IL2RA, CISH, and CDK 6) but repressed many other genes (e.g., IL7R, BCL6 ), whereas H9-RET had only weak stimulatory activity and H9-RETR had almost no effect ( Figure 16B and table S1, revealing both quantitative and qualitative differences in gene expression between full and partial agonist signals.
- H9-RET attenuated activity of H9-RET and negligible activity of H9-RETR, which effectively is a dominant-negative antagonist of IL-2.
- these molecules would inhibit not only endogenous IL-2, but also IL-15, which also signals via IL-2R ⁇ and ⁇ c .
- both H9-RET and H9-RETR inhibited IL-2-induced ( Figure 18A ) and IL-15-induced ( Figure 18B ) pSTAT5 in CD8 + T cells, with H9-RETR being more potent.
- H9-RET and H9-RETR Inhibition of pSTAT5 by H9-RET and H9-RETR treatment correlated with their lowering TCR-induced ( Figure 17 ) and IL-2-induced ( Figure 19A ) CD25 expression to levels below those observed in unstimulated control cells.
- H9-RET and H9-RETR inhibited IL-2-induced IL2RA mRNA expression ( Figure 19B ) as well as IL-2- and IL-15-induced proliferation ( Figure 19C ) in pre-activated human CD8 + T cells.
- H9-RETR inhibited IL-2 signaling
- H9-RETR would also inhibit TCR-induced cell proliferation, which is dependent on IL-2, and this was indeed the case ( Figure 20A ) and correlated with diminished CD25 expression ( Figure 20B ).
- IL-2 can promote Th1, Th9, and Treg differentiation but inhibit Th17 differentiation ( Liao et al., Immunity 38: 13 (2013 ))
- H9-RET and H9-RETR on these processes were examined. Strikingly, both H9-RET and H9-RETR inhibited Th1, Th9, and Treg differentiation but augmented Th17 differentiation ( Figure 21 ), underscoring their actions as potent antagonists of IL-2.
- H9-RETR The activation of primary human NK cells by IL-2 was also potently blocked by H9-RETR, as measured by IL-2-induced CD69 expression ( Figure 22A ) and cytotoxicity towards the breast cancer cell line HER18 ( Figure 22B ) and the chronic myelogenous leukemia cell line K562 ( Figure 22C ). Neither H9-RET nor H9-RETR stimulated CD69 expression or cytotoxicity by primary NK cells ( Figure 22A ).
- H9-RETR H9-RETR's effectiveness as an IL-2/IL-15 antagonist in vitro, we investigated its ability to antagonize the effects of endogenous cytokines in vivo. Because IL-2 has a short serum half-life ( Boyman et al., Nature Reviews Immunology 12: 180 (2012 )), H9-RETR was fused to the Fc fragment of human IgG4 (Fc4), an isotype with diminished antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP) ( Strohl, Current Opinion in Biotechnology 20: 685 (2009 )).
- ADCC/ADCP antibody-dependent cellular cytotoxicity/phagocytosis
- H9-RETR-Fc4 much more potently blocked IL-2- ( Figure 18C ) and IL-15-mediated ( Figure 18D ) pSTAT5 induction in pre-activated human CD8 + T cells and inhibited IL-2- ( Figure 18E ) and IL-15- ( Figure 18F ) induced proliferation of human CD8 + T cells.
- H9-RETR-Fc4 was as effective as the combination of anti-Tac and Mik ⁇ 1 in blocking IL-2 proliferation ( Figure 18E ) and more potent than Mik ⁇ 1 in inhibiting IL-15-induced proliferation ( Figure 18F ).
- H9-RETR-Fc4 The effectiveness of H9-RETR-Fc in vivo was next evaluated. Under steady-state conditions, Treg cells are the dominant population of primary cells expressing high affinity IL-2 receptors and can act as a systemic 'barometer' of IL-2 signaling. Pre-treatment of mice with H9-RETR-Fc4 prior to administering IL-2 or IL-15 significantly inhibited phosphorylation of STAT5 in CD4 + FoxP3 + Treg cells, as assessed ex vivo ( Figure 23 and Figure 18G ), indicating the in vivo potential of H9-RETR-Fc4 as an IL-2 antagonist.
- H9-RETR-Fc4 might inhibit lethal GVHD in a T cell-mediated C57BL/6-into-BALB/C model of fully-MHC mismatched bone marrow transplantation. Indeed, mice treated for 10 days with H9-RETR-Fc4 had longer survival than mice treated with isotype control Fc4 protein (P ⁇ 0.001)( Figure 18H ).
- HTLV-I Human T-cell lymphotropic virus-I causes adult T-cell leukemia (ATL), a malignant expansion of CD4 + T cells that exhibit an early growth phase that involves autocrine signals by IL-2 and IL-15 and paracrine signals by IL-9. Such cytokine-dependent proliferation is evident in patients with chronic and smoldering but not acute ATL ( Ju et al., Blood 117, 1938 (2011 )). As such the efficacy of H9-RETR in this system was tested. An ATL-derived cell line, ED40515, whose growth is supported in vitro by adding exogenous IL-2, was first used.
- H9-RETR potently inhibited proliferation of these cells, and was superior to daclizumab and Mik ⁇ 1 ( Figure 18I ).
- RETR 10 ⁇ g/ml was slightly more effective than daclizumab and considerably more effective than Mik ⁇ 1 ( Figure 18J ), underscoring its potential utility in the control of these vigorously proliferating malignant cells.
- Partial agonism defined as reduced signaling amplitude (E max ) at ligand saturation, is a pharmacological property typically associated with small molecules targeting GPCRs, channels, and other multi-pass transmembrane proteins.
- E max reduced signaling amplitude
- the notion of tunable signaling (partial agonism) through a type I transmembrane receptor dimer in response to a protein growth factor such as a cytokine has not been demonstrated.
- IL-2 variants were engineered by enhancing affinity at one receptor binding site (IL-2R ⁇ ), while attenuating interactions at the second receptor binding site ( ⁇ c ) in order to manipulate dimerization and signal initiation.
- IL-2R ⁇ induction as assessed ex vivo, prolonged survival in a GVHD model, and potently inhibited the spontaneous proliferation of peripheral blood T cells from a patient with smoldering ATL.
- H9-RETR also inhibited NK-mediated cytotoxicity.
- a larger repertoire of IL-2 variants may reveal an even broader spectrum of distinctive signaling activities, ranging from partial agonism to complete antagonism, and potentially including additional molecules with distinctive actions on T cell subsets, such as Treg versus effector T cells.
- Human IL-2 (amino acids 1-133) and variants thereof, the human IL-2R ⁇ ectodomain (amino acids 1-214), and the ⁇ c ectodomain (amino acids 34-232), were secreted and purified using a baculovirus expression system, as previously described ( Morgan et al., Science 193: 1007 (Sep 10, 1976 )). In brief, all construct sequences were cloned into the pAcGP67A vector (BD Biosciences) with an N -terminal gp67 signal peptide and a C-terminal hexahistidine tag.
- pAcGP67A vector BD Biosciences
- Spodoptera frugiperda (Sf9) insect cells cultured at 28°C in SF900 II SFM medium (Invitrogen) were transfected with the plasmid constructs to establish high titer recombinant virus, which was subsequently amplified.
- Trichopulsia ni (High-Five®) insect cells (Invitrogen) grown in Insect Xpress medium (Lonza) at 28°C were infected with the high titer viruses to express recombinant protein ( Zhu et al., Annual Review of Immunology 28: 445 (2010 ) and W. Liao et al., Nat Immunol 9: 1288 (2008 )).
- proteins were extracted via Ni-NTA (Qiagen) affinity chromatography, concentrated, and further purified to >98% homogeneity with a Superdex 200 sizing column (GE Healthcare) equilibrated in 10 mM HEPES (pH 7.3) and 150 mM NaCl.
- Fc4 and Fc4-RETR fusion proteins were also secreted and purified using this baculovirus expression system by cloning the human IgG4 Fc domain (Fc4) or the human IL-2 RETR variant followed by a C -terminal human IgG4 Fc domain (Fc4-RETR) into the pAcGP67A vector containing an N -terminal gp67 signal peptide and a C-terminal hexahistidine tag.
- the human IgG4 Fc domain was obtained from a modified pFUSE-hIgG4-Fc vector (Invivogen) with an engineered Ser228 Pro mutation ( Liao et al., Nat Immunol 12: 551 (2011 )).
- ⁇ c with a C -terminal biotin acceptor peptide (BAP)-LNDIFEAQKIEWHE was expressed and purified via Ni-NTA (Qiagen) affinity chromatography and then biotinylated with the soluble BirA ligase enzyme in 0.5 mM Bicine pH 8.3, 100 mM ATP, 100 mM magnesium acetate, and 500 mM biotin (Sigma). Proteins were purified by size exclusion chromatography on a Superdex 200 column (GE Healthcare), equilibrated in 10 mM HEPES (pH 7.3) and 150 mM NaCl.
- Binding interactions were characterized via surface plasmon resonance (SPR) studies using Biacore SA sensor chips (GE Healthcare) on a Biacore T100 instrument.
- ⁇ c was immobilized to the chip surface at low density (RU max ⁇ 100 response units), and serial dilutions of H9:IL-2R ⁇ or H9-RET:IL-2R ⁇ complexes were exposed to the surface for 60 s. Dissociation was then tracked for 200 s. An irrelevant biotinylated protein was immobilized in the reference channel to subtract non-specific binding from the measurements.
- Experiments were carried out in HBS-P+ buffer (GE Healthcare) supplemented with 0.2% BSA at 25°C.
- Unmodified YT 9 ( Zhu et al., Annual Review of Immunology 28: 445 (2010 )) and CD25 + YT-1 natural killer-like cells ( Liao et al., Nat Immunol 9: 1288 (2008 )) were cultured in RPMI complete medium (RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, minimum non-essential amino acids, sodium pyruvate, 25 mM HEPES, and penicillin-streptomycin (Gibco)). Both cell lines were maintained at 37°C in a humidified atmosphere with 5% CO 2 .
- the PE-stained CD25 + cells were then labeled with paramagnetic microbeads conjugated to an anti-PE IgG for 20 min at 4°C, washed once with cold FACS buffer, and sorted using an LS MACS separation column (Miltenyi Biotec) according to the manufacturer's protocol. Eluted cells were re-suspended and grown in RPMI complete medium and enrichment of CD25 + cells was evaluated using an Accuri C6 flow cytometer. Persistence of CD25 expression on the sorted CD25 + YT-1 cells was monitored by flow cytometric analysis using PE-conjugated anti-human CD25 antibody.
- Approximately 2 x 10 5 YT or CD25 + YT-1 cells were plated in each well of a 96-well plate, washed with FACS buffer, and re-suspended in FACS buffer containing serial dilutions of IL-2, H9, H9-RET, or H9-RETR. Cells were stimulated for 20 min at 37°C and immediately fixed by addition of formaldehyde to 1.5% followed by incubation for 10 min at room temperature. Cells were then permeabilized with 100% ice-cold methanol for 30 min at 4°C to allow for detection of intracellular signal effectors.
- the fixed and permeabilized cells were washed twice with FACS buffer and incubated with Alexa488-conjugated anti-STAT5 pY694 (BD Biosciences) or Alexa488-conjugated anti-ERK1/2 pT202/pY204 (BD Biosciences) diluted in FACS buffer for 2 hr at room temperature. Cells were then washed twice in FACS buffer and mean fluorescence intensity (MFI) was quantified on an Accuri C6 flow cytometer (BD Biosciences).
- MFI mean fluorescence intensity
- Dose-response curves were generated, and EC 50 and E max values were calculated using the GraphPad Prism data analysis software after subtraction of the MFI of unstimulated cells and normalization to the maximum signal intensity induced by cytokine stimulation.
- Buffy coats were obtained from healthy donors from the NIH Blood Bank, and peripheral blood mononuclear cells (PBMCs) were isolated by gradient centrifugation using lymphocyte separation medium (Mediatech, Inc., VA). Cells were isolated using the human CD8 + T-cell Isolation kit I (Miltenyi Biotec, Germany). For pre-activating cells, 6-well plates were pre-coated with 2 ⁇ g/ml of plate-bound anti-CD3 mAb (BD Biosciences).
- Cells were seeded at 1 x 10 6 cells/ml in complete medium (RPMI medium supplemented with glutamine, penicillin, streptomycin, and 10% FBS) with 1 ⁇ g/ml soluble anti-CD28 mAb (BD Biosciences) for 3 days and then rested for 48 h in fresh medium.
- Dose-response experiments on primary human CD8 + T cells were performed as previously described ( Liao et al., Immunity 38: 13 (2013 )); in brief, cells were treated with serial dilutions of IL-2, H9, H9-RET, H9-RETR, then fixed with Phosflow Fix Buffer I at room temperature for 10 minutes (BD Biosciences), and washed once with FACS buffer.
- Cells were then permeabilized by slowly adding cold BD PhosflowTM Perm Buffer III and incubated for 30 min on ice. Cells were washed and stained with PE-conjugated anti-STAT5 pY694 (BD Biosciences) or APC-conjugated anti-phospho-S6 ribosomal protein (Ser235/236) (clone D57.2.2E) at room temperature for 30 min in the dark, washed again with FACS buffer, and data acquired on a FACSCanto II flow cytometer (BD Biosciences) and analyzed by using FlowJo (Tree Star).
- PE-conjugated anti-STAT5 pY694 BD Biosciences
- APC-conjugated anti-phospho-S6 ribosomal protein Ser235/236
- C57BL/6 mice were from the Jackson Laboratory. Animal protocols were approved by the NHLBI Animal Care and Use Committee and followed the NIH Guidelines, "Using Animals in Intramural Research.” STAT5 phosphorylation was assayed using the manufacturer's protocol (BD Bioscience). In brief, IL-2 or IL-15 were injected i.p. into C57BL/6 mice, total splenocytes isolated, immediately fixed using BD PhosphoflowTM Lyse/Fix buffer, washed twice with ice cold PBS, stained using anti-CD4 and anti-CD25 antibodies (Biolegend), and then permeabilized using BD PhosFlow Perm Buffer III for 30 min on ice in the dark.
- IL-2, H9, H9-RET, or H9 RETR (1 ⁇ M) was incubated with 3 x 10 5 YT-1 cells in a 96-well plate for 2, 5, 10, 15, 30, 60, 90, 120, 180, or 240 min. Cells were immediately transferred to ice to prevent further receptor internalization and washed twice with ice-cold PBSA buffer (0.1% BSA in PBS). Cells were concurrently stained with 1:50 dilutions of allophycocyanin-conjugated anti-human IL-2R ⁇ antibody (TU27; Biolegend) and phycoerythrin-conjugated anti-human IL-2R ⁇ antibody (TUGh4; Biolegend) in PBSA buffer for 30 min on ice.
- TU27 allophycocyanin-conjugated anti-human IL-2R ⁇ antibody
- TAGh4 phycoerythrin-conjugated anti-human IL-2R ⁇ antibody
- Freshly isolated and pre-activated human CD8 + T-cells were stimulated with IL-2 in the absence or presence of H9-RET or H9-RETR, and pSTAT5 levels assessed.
- Cells were incubated with or without anti-Tac or Mik ⁇ 1, or Fc4-H9-RETR for 1 hr, then stimulated with a range of doses of IL-2 or IL-15 for 30 min, and pSTAT5 levels measured by flow cytometry.
- freshly isolated human NK cells (NK Cell Isolation Kit II, Miltenyi Biotech) were stimulated with serial dilutions of IL-15 in the presence or absence of the indicated IL-2 variant, and pSTAT5 assessed.
- CFSE Molecular Probes
- IL-2-dependent ED40515(+) ( Lenardo, Nature 353: 858 (1991 )) cells were washed twice with PBS. Cells were seeded into 96-well plates, at 1x10 4 cells/100 ⁇ l/well of RPMI 1640 medium with or without IL-2 and with or without reagents, and then incubated at 37 °C for 3 days.
- PBMCs Peripheral blood mononuclear cells
- ED40515(+) cells or ATL PBMCs were pulsed with 1 ⁇ Ci (0.037 MBq) [ 3 H]thymidine, then the cells were harvested with a cell harvester (Tomtec, Hamden, CT) and counted with a MicroBeta2 microplate counter (PerkEmer). The assay was performed in triplicate.
- PBMCs Peripheral blood mononuclear cells
- IL-2 analogues 1 ⁇ g/mL IL-2 analogues for 24 hours.
- Cells were then stained with APC-conjugated anti-CD56 (BD Biosciences), Pacific Blue-conjugated anti-CD3 (BioLegend), and FITC-conjugated anti-CD69 (BD Biosciences). Samples were analyzed by flow cytometry using a FACSAria II (BD Biosciences). NK cells were gated as CD3-negative, CD56-positive.
- PBMCs peripheral blood mononuclear cells
- NK cells peripheral blood mononuclear cells
- NK cells were added to 10,000 HER18 cells at a 10:1 effector:target ratio. Specific lysis was determined after 4 hours of culture in the presence of varying concentrations of IL-2 analogues.
- NK cells Lysis of K562 cells by primary NK cells was performed as described ( Yuan et al., Immunol Rev 259, 103 (2014 )).
- untouched human NK cells were purified using the human NK isolation kit (STEMCELL).
- K562 cells were labeled with the PKH67 green fluorescent cell linker kit (SigmaAldrich), NK cells were added to 5,000 K562 cells at a 10:1 ratio, cultured in the presence of varying concentrations of IL-2 analogues at 37 0 C for 4 h, and placed on ice to prevent further reactivity. Cells were then stained with propidium iodide (PI)(Sigma-Aldrich), and the percentage of PI + PKH67 + K562 cells was determined by flow cytometry.
- PI propidium iodide
- Naive CD4 + C57BL/6 T-cells were differentiated under different T-helper polarization conditions in the absence or presence of the indicated cytokines.
- cells were first stained for surface antigens as indicated and then stained with antibodies to IFN ⁇ (eBioscience), IL-17A (eBioscience), IL-4 (BioLegend), IL-9 (BioLegend), or FoxP3 (eBioscience) in BD cytofix and cytoperm, or eBioscience FoxP3 staining buffer kit according to the manufacturer's protocol. Stained cells were analyzed on a FACSCanto II flow cytometer (Becton Dickinson) using FlowJo software (Tree Star, Inc). All mouse cytokines were from Peprotech.
- RNA-seq libraries were prepared as described previously ( Liao et al., Immunity 38: 13 (2013 ). PCR amplified products were barcoded and sequenced using an Illumina HiSeq2000 platform.
- Pre-activated CD8 + T-cells were treated with different cytokines for 90 min and then chemically cross-linked with 1% paraformaldehyde. Chromatin from 10-20 million cells was sonicated into 250-500 bp fragments, immunoprecipitated with anti-STAT5B (Invitrogen) and processed for sequencing as described previously ( Noguchi et al., Cell 73: 147 (1993 )). All reads were aligned against the human genome (hg18, NCBI build 36.1) using Bowtie 0.12.4 ( Leonard, Nature Reviews. Immunology1:200 (2001 ). Uniquely mapped reads were converted to browser extensible data (BED) files and duplicated reads (multiple reads in same genomic location) were filtered. The filtered (non-redundant) BED files were then converted to binary tiled data (.tdf) and visualized using the Integrative Genome Viewer (Broad Institute).
- mice 7 week old female C57BL/6 (H 2 K b ) and BALB/c (H 2 K d ) mice from the NCI-Frederick Cancer Research Facility were maintained in a specific pathogen-free facility and treated according to an approved animal protocol approved by the NCI Animal Care and Use Committee.
- BALB/c mice were conditioned with 950 cGy total body irradiation and then reconstituted with 10 million T-cell depleted bone marrow cells from C57BL/6 mice alone or together with 2 million Treg-depleted pan-T cells.
- T cell depletion was performed with anti-CD90 [Thy1.2] microbeads (total T cell depletion) or anti-CD25 (Treg depletion) using kits from Miltenyi Biotec.
- mice receiving pan-T cells were additionally treated with Fc4 or H9-RETR-Fc4 (100 ⁇ g i.p. twice/day for 10 days).
- Drinking water was supplemented with ciprofloxacin from day -1 to +14 after total body irradiation. Survival and weight loss were monitored. Survival was analyzed according to the Kaplan-Meier method, and survival curves were compared using the log-rank test. Statistical analysis was performed using GraphPad Prism 4 software.
- IL-2 is referred to throughout the specification, one of skill in the art would appreciate that the methods and compositions described herein are equally applicable to other cytokines, for example, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, IL-3, IL-5, IL-6, or IL-15 with this property.
- GM-CSF granulocyte-macrophage colony-stimulating factor
- IL-2 granulocyte-macrophage colony-stimulating factor
- IL-6 IL-6
- IL-15 granulocyte-macrophage colony-stimulating factor
- the invention also includes mutants of GM-CSF, IL-2, IL-3, IL-5, IL-6, and IL-15 with increased binding affinity for their respective receptors, as compared to wild-type, and methods for identifying and using those mutants.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
- IL-2-Mutein mit einer größeren Bindungsaffinität für IL-2Rβ und einer reduzierten Bindungsaffinität für IL- 2Rγc-Rezeptor im Vergleich zu menschlichem IL-2 vom Wildtyp, wobei das IL-2-Mutein die Aminosäuresubstitutionen L18R, Q22E, L80F, R81D, L85V, I86V, I92F, Q126T und S130R umfasst.
- IL-2-Mutein nach Anspruch 1, wobei das Mutein eine reduzierte Fähigkeit zum Stimulieren einer STAT5-Phosphorylierung in einer T-Zelle IL-2Rβ+, optional einer T-Zelle CD8+, im Vergleich zu Wildtyp hIL-2 aufweist.
- IL-2-Mutein nach Anspruch 1, wobei das Mutein eine reduzierte Fähigkeit zum Stimulieren einer pERK1/ER 2-Signalisierung in einer Zelle IL-2Rβ+ im Vergleich zum Wildtyp hIL-2 aufweist.
- IL-2-Mutein nach Anspruch 1, wobei das Mutein ein IL-2- und/oder IL-15-Antagonist ist.
- IL-2-Mutein nach Anspruch 4, wobei das Mutein ein Hemmer von IL-2- und/oder IL-15 STAT5-Phosphorylierung in T-Zellen CD8+ ist.
- IL-2-Muteinfusionsprotein, umfassend das IL-2-Mutein nach Anspruch 1 verbunden mit einem menschlichen Fc-Antikörperfragment.
- Pharmazeutische Zusammensetzung, umfassend das IL-2-Mutein nach Anspruch 1 oder das IL-2-Mutein-Fusionsprotein nach Anspruch 6 und einen pharmazeutisch annehmbaren Träger.
- Pharmazeutische Zusammensetzung, umfassend das IL-2-Mutein nach Anspruch 1 und einen pharmazeutisch annehmbaren Träger zur Verwendung bei der Behandlung von Graftversus-Host-Krankheit (graft versus host disease, GVHD).
- Pharmazeutische Zusammensetzung, umfassend das IL-2-Mutein nach Anspruch 1 und einen pharmazeutisch annehmbaren Träger zur Verwendung bei der Behandlung von Adulter T-Zell-Leukämie.
- Pharmazeutische Zusammensetzung nach Anspruch 7, wobei die pharmazeutische Zusammensetzung das IL-2-Mutein nach Anspruch 1 umfasst.
- IL-2-Mutein nach Anspruch 4, wobei das Mutein ein Hemmer von durch IL-2 und/oder IL-15 induzierter Proliferation von T-Zellen CD8+ ist.
- IL-2-Mutein nach Anspruch 4, wobei das Mutein ein Hemmer von IL-2-abhängiger, TCR-induzierter Zellproliferation ist.
- IL-2-Mutein nach Anspruch 4, wobei das Mutein ein Hemmer von IL-2-abhängiger Th1-Th9- und/oder Treg-Differenzierung ist.
- IL-2-Mutein nach Anspruch 4, wobei das Mutein ein Promotor von Th17-Differenzierung ist.
- IL-2-Mutein nach Anspruch 4, wobei das Mutein ein Hemmer von IL-2-abhängiger Aktivierung von NK-Zellen ist.
- IL-2-Muteinfusionsprotein, umfassend das IL-2-Mutein nach Anspruch 1 und ein heterologes Polypeptid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461983973P | 2014-04-24 | 2014-04-24 | |
PCT/US2015/027635 WO2015164815A1 (en) | 2014-04-24 | 2015-04-24 | Superagonists, partial agonists and antagonists of interleukin-2 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3134102A1 EP3134102A1 (de) | 2017-03-01 |
EP3134102A4 EP3134102A4 (de) | 2017-11-15 |
EP3134102B1 true EP3134102B1 (de) | 2019-07-03 |
Family
ID=54333315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15782644.7A Active EP3134102B1 (de) | 2014-04-24 | 2015-04-24 | Superagonisten, partielle agonisten und antagonisten von interleukin-2 |
Country Status (6)
Country | Link |
---|---|
US (4) | US10150802B2 (de) |
EP (1) | EP3134102B1 (de) |
JP (4) | JP6592505B2 (de) |
CN (1) | CN106659757B (de) |
CA (1) | CA2946398A1 (de) |
WO (1) | WO2015164815A1 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
US11091527B2 (en) | 2017-12-06 | 2021-08-17 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
BR112015013557B1 (pt) | 2012-12-11 | 2021-12-14 | Albert Einstein College Of Medicine | Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante |
CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
CA2946398A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
CN107106654B (zh) | 2014-08-11 | 2021-06-11 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体 |
WO2017096262A1 (en) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CN109153728A (zh) * | 2016-03-21 | 2019-01-04 | 埃尔斯塔治疗公司 | 多特异性和多功能分子及其用途 |
AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
EP3458096A4 (de) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
AU2017335771A1 (en) | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
EP3565829A4 (de) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon |
AU2018234628B2 (en) | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
WO2019112852A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
WO2018234862A1 (en) * | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF |
AR112756A1 (es) | 2017-07-11 | 2019-12-11 | Synthorx Inc | Incorporación de nucleótidos no naturales, y su método |
CN111183149A (zh) * | 2017-08-03 | 2020-05-19 | 辛索克斯公司 | 用于治疗自身免疫疾病的细胞因子缀合物 |
BR112020009920A2 (pt) * | 2017-11-21 | 2020-12-15 | The Board Of Trustees Of The Leland Stanford Junior University | Agonistas parciais de interleucina-2 |
EP3737689A4 (de) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon |
EP3768698A4 (de) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Verfahren und zusammensetzungen mit tumorsuppressorgentherapie und cd122/cd132-agonisten zur behandlung von krebs |
SG11202011309SA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable interleukin 12 polypeptides and methods of use thereof |
CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
WO2019246404A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
US10703776B2 (en) | 2018-08-06 | 2020-07-07 | Medikine, Inc. | IL-2RBeta binding compounds |
SI3849614T1 (sl) * | 2018-09-11 | 2024-04-30 | Ambrx, Inc. | Polipeptidni konjugati interlevkina-2 in njihove uporabe |
CN112105633B (zh) * | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
US20220017588A1 (en) * | 2018-11-20 | 2022-01-20 | University Of Washington | Split interleukin mimetics and their use |
MX2021009259A (es) | 2019-02-06 | 2021-08-24 | Synthorx Inc | Conjugados de il-2 y metodos de uso del mismo. |
WO2020198293A1 (en) * | 2019-03-25 | 2020-10-01 | Northshore University Health System | Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer |
CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
US20240102047A1 (en) * | 2019-10-11 | 2024-03-28 | Tilt Biotherapeutics Oy | An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide |
CA3160133A1 (en) * | 2019-11-05 | 2021-05-14 | Medikine, Inc. | Il-2rbyc binding compounds |
IL292803A (en) | 2019-11-05 | 2022-07-01 | Medikine Inc | Compounds that bind to both 2-il and 7-il receptors, preparations containing them and their uses |
MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
CA3166509A1 (en) * | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
CN115315435A (zh) | 2020-02-03 | 2022-11-08 | 麦地金公司 | IL-7Rαγc结合化合物 |
IL295303A (en) | 2020-02-03 | 2022-10-01 | Medikine Inc | 7-il alpha receptor binding compounds and preparations containing them |
IL295811A (en) * | 2020-03-05 | 2022-10-01 | Univ Leland Stanford Junior | designed variants of il-2 |
EP4122951A4 (de) * | 2020-03-19 | 2024-05-29 | Innovent Biologics (Singapore) Pte. Ltd. | Interleukin-2-mutant und verwendung davon |
US11746137B2 (en) * | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
AU2021299552A1 (en) * | 2020-07-02 | 2023-02-02 | Inhibrx Biosciences, Inc. | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
CN112048018B (zh) * | 2020-08-31 | 2021-10-08 | 南方医科大学 | 一种嵌合t细胞生长因子及其应用 |
JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ, インコーポレイテッド | 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法 |
EP4229077A2 (de) * | 2020-10-14 | 2023-08-23 | Cytimm Therapeutics, Inc. | Modifizierte interleukin-2 (il-2)-polypeptide und verfahren zur herstellung und verwendung davon |
US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
KR20240024829A (ko) | 2021-05-19 | 2024-02-26 | 애셔 바이오테라퓨틱스, 인크. | Il-21 폴리펩타이드 및 표적화된 작제물 |
US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
EP4366781A1 (de) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | An il-2 konjugierte checkpoint-inhibitoren und verwendungen davon |
JP2024529297A (ja) | 2021-07-09 | 2024-08-06 | ブライト ピーク セラピューティクス エージー | Il-2を有するチェックポイント阻害剤のコンジュゲート及びその使用 |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
US20240132563A1 (en) | 2022-02-23 | 2024-04-25 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
WO2024057094A2 (en) * | 2022-09-14 | 2024-03-21 | Medicenna Therapeutics, Inc. | Il-2 superantagonists constructs, methods and uses thereof |
WO2024146575A1 (zh) * | 2023-01-04 | 2024-07-11 | 北京晶泰科技有限公司 | 白细胞介素-2变体及其应用 |
WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816249A (en) | 1981-11-17 | 1989-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
EP0091539B2 (de) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5068177A (en) | 1983-12-28 | 1991-11-26 | Scripps Clinic And Research Foundation | Anti-idiotype antibodies induced by synthetic polypeptides |
US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5227159A (en) | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
NZ234674A (en) | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
ATE342356T1 (de) | 1992-11-05 | 2006-11-15 | Sloan Kettering Inst Cancer | Prostata-spezifisches membranantigen |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
HUP0202442A3 (en) | 1999-08-09 | 2005-01-28 | Lexigen Pharmaceuticals Corp L | Multiple cytokine-antibody complexes |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
AU7756100A (en) | 1999-10-08 | 2001-04-23 | Curagen Corporation | Interleukin-2 like protein and nucleic acids encoding same |
EP1230378B1 (de) | 1999-11-15 | 2007-06-06 | Onyx Pharmaceuticals, Inc. | Ein oncolytisches adenovirus |
AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
CN100390282C (zh) * | 2001-12-04 | 2008-05-28 | 默克专利有限公司 | 具有调节的选择性的il-2融合蛋白 |
US6894527B1 (en) | 2003-05-12 | 2005-05-17 | Xilinx, Inc. | Evolved circuits for bitstream protection |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
US20060234205A1 (en) | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
WO2006081510A2 (en) | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics Inc. | Methods for treating renal cell carcinoma |
JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | Gitr結合分子およびその使用 |
EP2161336B2 (de) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US20100317577A1 (en) | 2005-09-09 | 2010-12-16 | Department Of Health And Human Services | Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation |
WO2009046104A1 (en) | 2007-10-01 | 2009-04-09 | University Of Miami | Aptamer-targeted sirna to prevent attenuation or suppression of t cell function |
WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
EP2057972A1 (de) | 2007-11-07 | 2009-05-13 | N.V. Organon | Intrauterine Vorrichtung |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
US20100183545A1 (en) | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
DK4209510T5 (da) | 2008-12-09 | 2024-07-22 | Hoffmann La Roche | Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion |
EP2382228B1 (de) | 2009-01-21 | 2020-08-26 | Amgen Inc. | Zusammensetzungen und verfahren zur behandlung von entzündungs- und autoimmunerkrankungen |
PE20120211A1 (es) | 2009-02-17 | 2012-03-24 | Ucb Pharma Sa | Anticuerpos que tienen especificidad por ox40 humana |
CU23734A1 (es) * | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
AU2011239706B2 (en) | 2010-04-13 | 2015-08-20 | Celldex Therapeutics Inc. | Antibodies that bind human CD27 and uses thereof |
BR112013005699B1 (pt) | 2010-09-09 | 2021-08-17 | Pfizer Inc | Anticorpo isolado ou porção de ligação ao antígeno do mesmo que se liga ao 4-1bb humano, combinação, usos dos mesmos, bem como composição farmacêutica, molécula de ácido nucleico isolada e vetor |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
US20160354472A1 (en) | 2010-10-22 | 2016-12-08 | Protox Therapeutics Corp. | Use of human serum albumin to decrease antigenicity of therapeutic proteins |
CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
WO2012119093A1 (en) | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
SI2785375T1 (sl) | 2011-11-28 | 2020-11-30 | Merck Patent Gmbh | Protitelesa proti PD-L1 in uporabe le-teh |
WO2014064240A1 (en) | 2012-10-26 | 2014-05-01 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
ES2868247T3 (es) | 2013-02-15 | 2021-10-21 | Univ California | Receptor de antígeno quimérico y métodos de uso del mismo |
JP6636920B2 (ja) | 2013-07-16 | 2020-01-29 | ジェネンテック, インコーポレイテッド | Pd−1軸結合アンタゴニスト及びtigit阻害剤を使用するがんの治療方法 |
CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
US10711272B2 (en) | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
JP6752148B2 (ja) | 2014-02-07 | 2020-09-09 | マクマスター ユニバーシティー | 三官能性t細胞−抗原カプラ及び方法並びにこれらの使用 |
CA2946398A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
JP2018510151A (ja) | 2015-03-06 | 2018-04-12 | ソレント・セラピューティクス・インコーポレイテッド | Tim3に結合する抗体医薬 |
EP3268037B1 (de) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
EP3387155A4 (de) | 2015-12-10 | 2019-06-12 | Definiens AG | Verfahren zur behandlung und auswahl von patienten, die auf eine immunvermittelte krebstherapie ansprechen |
CN116514976A (zh) | 2016-03-04 | 2023-08-01 | Jn生物科学有限责任公司 | 针对tigit的抗体 |
-
2015
- 2015-04-24 CA CA2946398A patent/CA2946398A1/en active Pending
- 2015-04-24 CN CN201580033661.7A patent/CN106659757B/zh active Active
- 2015-04-24 JP JP2017507931A patent/JP6592505B2/ja active Active
- 2015-04-24 US US15/305,831 patent/US10150802B2/en active Active
- 2015-04-24 EP EP15782644.7A patent/EP3134102B1/de active Active
- 2015-04-24 WO PCT/US2015/027635 patent/WO2015164815A1/en active Application Filing
-
2018
- 2018-10-30 US US16/175,709 patent/US10654905B2/en active Active
-
2019
- 2019-09-20 JP JP2019172064A patent/JP7307919B2/ja active Active
-
2020
- 2020-05-12 US US15/930,057 patent/US11384131B2/en active Active
-
2021
- 2021-12-28 JP JP2021213818A patent/JP7503794B2/ja active Active
-
2022
- 2022-05-26 US US17/825,660 patent/US20230002467A1/en active Pending
-
2024
- 2024-05-31 JP JP2024088571A patent/JP2024113005A/ja active Pending
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US11466068B2 (en) | 2017-05-24 | 2022-10-11 | Pandion Operations, Inc. | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11091527B2 (en) | 2017-12-06 | 2021-08-17 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11091526B2 (en) | 2017-12-06 | 2021-08-17 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11779632B2 (en) | 2017-12-06 | 2023-10-10 | Pandion Operation, Inc. | IL-2 muteins and uses thereof |
US11945852B2 (en) | 2017-12-06 | 2024-04-02 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11965008B2 (en) | 2017-12-06 | 2024-04-23 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
Also Published As
Publication number | Publication date |
---|---|
CA2946398A1 (en) | 2015-10-29 |
US20170044229A1 (en) | 2017-02-16 |
US11384131B2 (en) | 2022-07-12 |
JP7503794B2 (ja) | 2024-06-21 |
EP3134102A1 (de) | 2017-03-01 |
US20230002467A1 (en) | 2023-01-05 |
US10654905B2 (en) | 2020-05-19 |
JP2022046693A (ja) | 2022-03-23 |
US20210079055A1 (en) | 2021-03-18 |
US10150802B2 (en) | 2018-12-11 |
JP2017518361A (ja) | 2017-07-06 |
US20190119346A1 (en) | 2019-04-25 |
JP2020023506A (ja) | 2020-02-13 |
WO2015164815A1 (en) | 2015-10-29 |
CN106659757B (zh) | 2022-01-28 |
CN106659757A (zh) | 2017-05-10 |
JP2024113005A (ja) | 2024-08-21 |
JP6592505B2 (ja) | 2019-10-16 |
CN106659757A8 (zh) | 2017-07-07 |
EP3134102A4 (de) | 2017-11-15 |
JP7307919B2 (ja) | 2023-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11384131B2 (en) | Superagonists, partial agonists and antagonists of interleukin-2 | |
US12006347B2 (en) | Superagonists and antagonists of interleukin-2 | |
US7569215B2 (en) | Mutant interleukin-2 (IL-2) polypeptides | |
WO2012119093A1 (en) | Superagonists and antagonists of interleukin-2 | |
EP2882449B1 (de) | Superkine und synthekine: umdisponierte cytokine mit neuen und verstärkten signalisierungsaktivitäten | |
WO2021178833A2 (en) | Designed il-2 variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20161104 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171017 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/55 20060101ALI20171011BHEP Ipc: A61K 38/00 20060101AFI20171011BHEP Ipc: A61K 38/20 20060101ALI20171011BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180619 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVI Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO |
|
INTG | Intention to grant announced |
Effective date: 20190115 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1150160 Country of ref document: AT Kind code of ref document: T Effective date: 20190715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015033174 Country of ref document: DE |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVI Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI AND CIE SA, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190703 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1150160 Country of ref document: AT Kind code of ref document: T Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191003 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191104 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191003 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191004 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015033174 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
26N | No opposition filed |
Effective date: 20200603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200424 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200424 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230522 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240423 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240606 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240501 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240429 Year of fee payment: 10 |